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ABSTRACT 
Non-Hodgkin lymphoma (NHL) is a heterogeneous group of malignant diseases arising from 
lymphocytes. There are about 40 subtypes according to the World Health Organizations 
classification system, differing in morphology, immunophenotype, genetic and/or clinical 
features.  
Immunodeficiency, family history, autoimmune disease and some infectious agents are 
established risk factors for NHL. For most incident NHL patients, however, the reason is not 
known. One of the most common NHL subtypes, follicular lymphoma (FL), has been 
associated with smoking in most but not all studies. FL risk is strongly associated with 
germline genetic variation in the human leukocyte antigen (HLA) DRB1 gene, and amino-
acid variation in certain positions of the HLA-DRB1 molecule. In Study I, we used a case-
control study design to test the hypothesis that smoking is a risk factor for FL among 
individuals with certain amino-acid combinations in HLA-DRB1, including in positions 70-74 
(known as the shared epitope (SE) in rheumatoid arthritis). We found that individuals that 
carried two SE alleles and were former or current smokers had approximately 2 and 3,5 
times increased risk of FL, respectively, as compared to individuals that carried zero SE 
alleles and never smoked. The interaction was significant when assessed by estimating the 
attributable proportions of interaction (0.15≤ APoverall≤1.0; 0.005≤ APwomen≤1.0). This finding 
provides further evidence for a role of smoking in follicular lymphomagenesis, and offers a 
new model to explore FL etiology.   
The prognosis of NHL not only varies by subtype, but also within subtypes for reasons that 
we do not fully understand. Prognostic indices are commonly used in NHL to guide choice of 
treatment and predict disease course. These include the host factors age and performance 
status along with indicators of tumor burden, and provide a rough estimation of outcome. 
Other host factors such as lifestyle factors and medical history as well as host genetic 
variation are being explored for their potential contribution to better prognostic prediction. 
This was the focus of Study II-IV.  
In Study II, we tested the hypothesis that smoking status, attained education (proxy for 
socioeconomic status), body mass index, ultraviolet radiation exposure, autoimmune 
disease or family history of hematopoietic malignancy influenced overall and lymphoma-
related survival among NHL patients overall and major subtypes. We found evidence that 
current smoking, few years of attained education and history of autoimmune disease 
increased the risk of all-cause death among NHL patients overall. Smoking also increased the 
risk of death among patients with diffuse large B-cell lymphoma. Attained education was 
also associated with lymphoma-related death. Further studies are needed to understand 
mechanisms for these associations and how they should be accounted for in the clinical 
setting.  
In Study III, we tested the hypothesis that single nucleotide polymorphisms (SNPs) have an 
impact on FL survival or progression by 1) conducting a meta-analysis of two GWAS, and 2) 
exploring 22 SNPs previously reported to be associated with FL outcome. In the meta-
analysis, no SNP was associated with FL survival at genome-wide significance, although one 
SNP in the ABCA10 gene on chromosome 17 was borderline associated (rs10491178: 
Prandom= 5.24 x10-8). In line with previous studies, two linked SNPs in IL8 and one in CD46 
were negatively associated with FL progression. Our results mainly provide further evidence 
of an impact of SNPs involved in immune functions on follicular lymphoma outcome. 
  
In Study IV, we further investigated the hypothesis that inherited factors influence survival 
among patients with a lymphoid malignancy by testing concordance in survival between two 
first-degree relatives with lymphoid malignancies. We found that individuals with a first-
degree relative with good prognosis had a better survival than individuals with a first-degree 
relative with expected or poor survival among individuals with the same broad type of 
lymphoid malignancy, especially indolent lymphomas. Our results support a role of 
heritability in the outcome primarily of indolent lymphomas.    
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1 INTRODUCTION  
Lymphoma is a heterogeneous group of malignant diseases arising in cells destined to 
become lymphocytes. Broadly, they are divided into Hodgkin (10%), B cell (80%) and T/NK 
cell (10%) lymphomas. B and T/NK cell lymphomas are collectively still often referred to as 
non-Hodgkin lymphoma (NHL), even though this term is no longer used in the most updated 
version of the World Health Organization (WHO) classification system of lymphoid 
malignancies.1 NHL as a group is among the top 10 most common cancer types worldwide 
and is estimated to account for approximately 3% of the world’s cancer-related deaths.2 It is 
a heterogeneous group of 40 subtypes, however, with distinct biology and clinical behavior.3 
These are divided into precursor and mature lymphoid malignancies, distinguished by the 
absence (precursor) or presence (mature) of completely rearranged immunoglobulin (B cell 
neoplasms) or T cell receptor genes (T cell neoplasms). Of note, the most recent WHO 
classifications of lymphoid malignancies also include chronic lymphocytic leukemia and 
plasma cell tumors (multiple myeloma and plasmocytoma) among mature B cell lymphoma. 
Although NHL is the main focus of this thesis, in Study IV we include all lymphoid neoplasms, 
i.e. Hodgkin lymphomas as well as precursor and mature B and T/NK cell lymphomas.  
 
The vast number of different NHL subtypes complicates epidemiological studies of their risk 
and prognosis, as one factor may be important to one subtype but not another, and each 
subtype by itself is more or less uncommon.3 Another complicating factor is that the 
lymphoma classification system has changed several times throughout history, which makes 
comparisons over time complicated. For these reasons, epidemiological studies are still 
done on NHL as a group but increasingly by subtype with as much detail as possible. The 
relatively small number of patients diagnosed with a certain subtype each year has driven 
researchers in lymphoma epidemiology to international collaboration. The studies 
constituting this thesis were performed in this context. Hence, they were both performed 
among all lymphoid malignancies combined (Study IV), all NHL combined (Study II), as well 
as among subtypes of these with as much details as possible (Study II and IV). Two studies 
(Study I and III) focused completely on follicular lymphoma. Two of the studies were done in 
collaboration with researchers in other countries: Denmark (Study I and III), the United 
States of America (USA; Study III) and Singapore (Study I and III).  
 
The last two decades, our knowledge have increased considerably about the genetic events 
and aberrations in the lymphocytes, as well as biological mechanisms in lymphomagenesis. 
We have also learnt about some host factors (genetic and environmental) that are 
consistently associated with increased risk of NHL in general and in specific subtypes. 
However, for most of our patients we still do not know what caused the lymphoma.  
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The prognosis of NHL is highly variable by subtypes but also within subtypes for reasons that 
are mostly unknown. Many new prognostic factors have been proposed but so far few have 
been validated. In clinical practice and clinical trials, international prognostic indexes based 
on some host (commonly age and performance status) and tumor factors (usually stage and 
other measures of disease burden) are the most widely used tools to stratify patients into 
prognostic groups. There is great overlap between these prognostic groups, however, and in 
consulting our patients we can only make general statements about the prognosis. 
Information on host factors other than age, sex and performance status would be readily 
available and provide a simple way to improve prognostic prediction, should they be proven 
to carry such information. This has led up to researches exploring host factors in lymphoma 
prognosis in recent years.      
 
In Study I, we tested the hypothesis that smoking is a risk factor for follicular lymphoma in 
individuals carrying certain amino-acid combinations in the human leukocyte antigen (HLA) 
DRB1 molecule but not otherwise. In Study II, we investigated the potential prognostic 
impact of selected host factors among NHL patients and four subtypes. In Study III, we 
explored the potential prognostic impact of host genetic polymorphisms across the germline 
genome on follicular lymphoma outcome. In Study IV, we further explored the hypothesis 
that inherited genetic polymorphisms influence survival in patients with a lymphoid 
malignancy, by testing if there was concordance in survival time between two first-degree 
relative with such a malignancy. 
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2 BACKGROUND 
 
2.1 LYMPHOCYTES 
Lymphocytes are white blood cells that defend our bodies against infections, toxins and 
tumor development.4 There are about 2 x 1012 lymphocytes in the human body, a cell mass 
comparable to that of the brain or liver.4 The mature lymphocyte continuously circulate 
from the blood to the lymph system and back, awaiting contact with a foreign antigen 
(Figure 1).  
 
Figure 1. The lymph system and lymphoid organs.  
 
Lymphocytes are divided into three functional types: B (bone marrow-derived) cells, T 
(thymus-derived) cells and NK (natural killer) cells (Figure 2). B cells make antibodies against 
extracellular antigens, such as bacteria and toxins.4 Cytotoxic T cells (CD8+ T cells) attack 
normal cells infected by viruses or cells that have become neoplastic.4 Helper T cells (CD4+ T 
cells) assist in the activation of B and cytotoxic T cells upon exposure to a foreign antigen.4 
While each B and T cell is specific to a certain antigen presented to them by HLA class I and II 
molecules (adaptive immunity), NK cells attack cells that show signs of stress, such as low 
expression of HLA molecules due to viral infection or malignant transformation (innate 
immunity).4  
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Figure 2. The hematopoiesis. Lymphoid malignancies originate from the lymphoid cell line, 
which starts with the common lymphoid progenitor.   
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2.2 ETIOLOGY OF NON-HODGKIN LYMPHOMA  
The incidence of NHL increased considerably in many high income countries between 1950 
and 1990.5 The increase now seems to have levelled off but it sparked intense 
epidemiological research with the aim to explain it. When considering lymphoma risk 
factors, it is important to remember that lymphoma is a group of heterogeneous diseases 
that may or may not share risk factors with other lymphoma subtypes. Established risk 
factors are HIV infection, organ transplant, primary immunodeficiency disorders, 
autoimmunity and chronic inflammatory disorders, Helicobacter pylori, Hepatitis C virus, 
Human T cell leukemia/lymphoma virus 1, Human herpes virus 8 and breast implants. Host 
factors such as family history of lymphoma and germline genetic polymorphisms are also 
well-established risk factors of NHL subtypes. Lifestyle factors such as cigarette smoking, 
high body mass index and ultraviolet radiation constitute probable risk factors of NHL. The 
following sections discuss risk factors with relevance for this thesis, although other factors 
may also be implicated in NHL risk according to previous studies.6-10  
 
2.2.1 Lifestyle factors 
Recent pooled analyses from the InterLymph consortium are among the largest studies on 
lifestyle factors in risk of lymphoma to date.6-10 Although other, smaller studies (some of 
which are included in the pooled InterLymph studies), exist, results from the InterLymph 
studies and the Scandinavian Lymphoma Etiology (SCALE) study (see 4.1 for details) are 
presented in Table 1 to illustrate the typical association between each factor and NHL risk.  
 
2.2.1.1 Tobacco smoking 
The pooled InterLymph analysis demonstrated that smoking was associated with risk of 
follicular lymphoma among women only but not among men and not with other subtypes or 
all non-Hodgkin lymphomas combined (Table 1).7 This is in line with some previous smaller 
studies, including SCALE (Table 1).11 The mechanism behind this association and why it 
differs by sex is unclear. Study I of this thesis addressed this issue by testing the hypothesis 
that smoking is a risk factor for follicular lymphoma among individuals that carry certain 
germline genetic variation in the HLA-DRB1 molecule but not otherwise. Given that 
lymphoma risk is increased in individuals with immune deficiencies, chronic inflammatory 
and autoimmune disorders (as outlined below), it is noteworthy that smoking has such 
effects on our immune systems (Figure 3).12  
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Figure 3. From Arnson, Shoenfeld and Amital, Journal of Autoimmunity 2010,12 illustrating 
the effects of cigarette smoking on the immune system. Cigarette smoking both increases 
inflammatory allergic and autoimmune reactions and decreases activity against infections. 
Reprinted with permission. 
 
2.2.1.2 Obesity  
The parallel increase in NHL incidence and BMI in the populations in the western world led 
researchers to investigate whether there was an etiological link between the two. Several 
studies, including SCALE (Table 1),13 have demonstrated an association between obesity and 
risk of NHL overall and diffuse large B cell lymphoma, while some studies have found no 
association (reviewed by Chiu and Hou, 201514). The pooled analyses from InterLymph6-10 
confirms the association between high BMI in adulthood and risk of diffuse large B cell 
lymphoma but not the risk of all NHL combined (Table 1). High BMI in young adulthood 
resulted in larger relative risk estimates, however, and was also significantly associated with 
risk of NHL overall and follicular lymphoma (Table 1). Obesity is associated with low grade 
chronic inflammation15 and thus sustained activation of the immune system. Given the well-
established increase of lymphoma risk associated with chronic inflammatory disorders, as 
outlined above, the results from the InterLymph and other studies seem plausible.   
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2.2.1.3 Ultraviolet light 
The incidence of skin cancers (malignant melanoma, squamous cell and basal cell 
carcinoma) increased in parallel with lymphoma incidence.16 This fact together with the 
observation that NHL risk increased after the diagnosis of a skin cancer and vice versa 
(reviewed by Hu et al 200516) led to the hypothesis that ultraviolet (UV) radiation could 
contribute to lymphomagenesis. Presumably to many researchers surprise, however, most 
studies support a protective effect of exposure to UV radiation on risk of NHL overall, diffuse 
large B cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia (Table 1).8,17 
The mechanisms behind these observations are not clear. UV radiation of the skin has 
immune modulatory effects, including inhibition of antigen presentation, activation of 
innate immune responses and suppression of adaptive immune function. Whether these are 
mediated solely by inducing vitamin D synthesis or through other mechanisms is not 
completely understood.18 Interestingly, lower doses of UV light (“suberythemal”) seem to 
inhibit local immune responses, while higher doses (“erythemal”) seem to achieve systemic 
immune effects.18        
 
2.2.2 Host factors 
2.2.2.1 Familial aggregation 
Results from many case-control, cohort and registry-based studies suggest that an individual 
with a first-degree relative with a lymphoma has about two to three times the risk of 
lymphoma as compared to individuals without such family history (reviewed by Cerhan and 
Slager 201519). Although these studies cannot exclude that shared environmental risk 
factors explain the observations, it is likely that germline polymorphisms contribute to 
lymphoma risk to some extent. The largest pooled analysis to date supports this notion for 
several NHL subtypes, including diffuse large B cell lymphoma, follicular lymphoma, chronic 
lymphocytic leukemia and mantle cell lymphoma (Table 1).8 Interestingly, the associations 
are stronger when looking at familiar cases with concordant NHL subtypes, suggesting that 
inherited genetic factors may be subtype specific.19   
 
2.2.2.2 Germline genetic variation 
Many candidate gene studies and genome-wide association studies (GWAS) have searched 
for and found germline genetic polymorphisms associated with risk of NHL overall and/or its 
subtypes (reviewed by Cerhan and Slager 201519). To date, at least 67 SNPs (where one 
nucleotide in the DNA sequence is exchanged for another) in 41 loci have been identified in 
GWAS.19 Few SNPs identified in candidate gene studies have been replicated in GWAS,19 
indicating many false positive findings with the former study design. Most of the 67 SNPs  
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Table 1. Risk factors in NHL overall and subtypes in previously published studies.    
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are specific to subtypes.19 Each SNP has low impact on NHL risk (relative risk of 0.5-2)19 but 
carrying several risk SNPs could possibly lead to larger risk increases. Identifying risk SNPs 
may also eventually shed light on lymphoma etiology. It is noteworthy that the HLA region 
at 6p:21 is the most frequently recurring region across GWAS and lymphoma subtypes 
(Hodgkin, follicular, marginal zone, diffuse large B cell lymphoma and chronic lymphocytic 
leukemia).19  
 
The SNPs most strongly associated with follicular lymphoma risk have been found in the HLA 
class II region.19 Further analyses of this region indicate that the observed association may 
be explained by amino-acid variation in the antigen binding groove of the HLA-DRB1 
molecule (Figure 4).20,21 In particular, amino-acid positions 11, 13, 28 and 30 have been 
strongly and independently associated with follicular lymphoma risk.20 These positions are 
important for antigen binding and presentation by specialized antigen presenting cells to 
helper T cells, implying importance of these immune functions in follicular 
lymphomagenesis. Interestingly, amino-acid variation in HLA-DRB1 is a strong risk factor for 
rheumatoid arthritis too (position 70-74, the shared epitope; Figure 4). Furthermore, this 
risk factor interacts with smoking in a profound way in rheumatoid arthritis (RA) risk.22,23 
This is the basis for the hypothesis tested in Study I.   
 
 
Figure 4. Three dimensional ribbon model of the HLA-DR antigen binding groove. Amino-
acid positions 11, 13, 28 and 30 as well as the shared epitope (70-74) are highlighted. The 
figure was created using UCSF Chimera 24 and based on the Protein Data Bank entry 4GBX 25.  
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2.2.3 Genetic events 
In lymphoma, like other tumors, malignant transformation events include alterations of the 
genome, such as gene amplifications, deletions and point-mutations.26-28 In addition, most 
lymphomas carry chromosomal translocations and B-cell lymphomas in particular also 
aberrant somatic hypermutations, both of which arise by mechanisms fundamental for the 
normal B- and T-cell development.26,27 The germline immunoglobulin and T cell receptor 
genes contain segments coding for the antigen recognizing part of the final molecule: the 
variable (V), diversity (D) and joining (J) segments (Figure 5 A).29,30 During normal 
lymphocyte development, rearrangement of these gene segments is a prerequisite to 
produce a large repertoire of B and T cells with distinct immunoglobulin and T cell receptor 
specificities.29,30 The downside of this cutting and pasting of genes is the risk of mistakes that 
sometimes lead to the placement of a promotor and/or enhancer juxtaposed to an 
oncogene, causing dysregulated gene expression of the latter (Figure 5 B).26,27 Additionally, 
in normal B-cell development, somatic hypermutation of the variable region of the 
immunoglobulin gene further increases antigen affinity.26 However, aberrant somatic 
hypermutations in other genes occur in B cell lymphomagenesis, sometimes altering the 
regulation and/or function of the affected genes or gene products.26    
 
   
Figure 5, from Dyer et al, Blood 2010.31 (A) The normal immunoglobulin heavy chain locus at 
14q. The V, D and J segments are recombined to produce the gene for specific antigen 
recognition. The VDJ unit is further combined with constant (C) gene segments. (B) The 
normal process of cutting and pasting segments of the immunoglobulin genes (or the T cell 
receptor gene in T cells) involves a risk of errors that sometimes places an oncogene under 
the control of the promotor or enhancers of an immunoglobulin gene, leading to aberrant 
expression of the former. Reprinted with permission of ASCO 2017.   
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2.2.4 Microenvironment  
The microenvironment of pre-malignant (and malignant) lymphocytes contains normal 
inflammatory cells that interact with the neoplastic cells through cell-cell contact and 
soluble mediators such as cytokines and chemokines (Figure 6).32 This interaction stimulates 
cell survival, cell growths and invasion, induce angiogenesis and suppresses anti-tumor 
immunosurveillance.32,33 Important oncogenic pathways are activated, including PI3K/AKT, 
STAT3, Hh and NF-κB.32 Although the exact mechanisms are not yet known, the link 
between the microenvironment and lymphomagenesis is clear and is believed to be as 
important as somatic genetic aberrations for the development of many lymphoma 
subtypes.34     
 
2.2.5 The B cell receptor  
The B cell receptor is essential for normal B cell development and maturation.35 It is also 
increasingly recognized as essential in the development (and sustainment) of many B cell 
malignancies.35 Signals through the B cell receptor pathways stimulate survival, 
proliferation, migration and resistance to apoptosis.35 In lymphomagenesis, these pathways 
may be constitutively activated by chronic antigen simulation by microbial antigens (e.g. 
Helicobacter pylori in gastric MALT lymphoma) or self-antigens (e.g. myosin in chronic 
lymphocytic leukemia), or activating mutations in intracellular components of the B cell 
receptor (e.g. CARD11 in activated B-cell-like (ABC) diffuse large B cell lymphoma).35,36 The 
continuous B cell receptor signaling creates a permissive environment for genetic instability 
and accumulation of mutations that may lead to tumor initiation and progression.     
 
2.2.6 Autoimmune and chronic inflammatory disorders  
Autoimmune and chronic inflammatory disorders such as RA, systemic lupus erythematosus 
(SLE), primary Sjögren’s syndrome and celiac disease increase the risk of lymphoma several 
times as compared to the general population.37 Interestingly, the more systemic 
inflammatory conditions RA and SLE have been associated mainly with diffuse large B cell 
lymphoma, while the more localized inflammatory conditions primary Sjögrens syndrome 
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Figure 6, from Scott and Gascoyne 2014,38 illustrating the typical microenvironment of the 
three B cell lymphomas that represent the extremes of the spectrum of tumor 
microenvironment (referred to as “recruitment”, “re-education” and “effacement”). The 
ratio of malignant to normal cells increases across the range from classical Hodgkin 
lymphoma (approximately 1% tumor cells) to Burkitt lymphoma (>90% tumor cells). The 
ratio correlates with the dependence of the tumor cells on support from normal cells in the 
microenvironment. Reprinted by permission from Macmillan Publishers Ltd on behalf of 
Cancer Research UK: Nature Reviews Cancer,38 copyright 2017. 
 
and celiac disease are associated with marginal zone lymphoma of MALT type in salivary 
glands and enteropathy-associated T cell lymphoma in the intestine, respectively.37 This 
observation suggests different mechanisms of lymphomagenesis for systemic and local 
inflammatory conditions. The biological mechanisms behind the increased risks are not 
known but available evidence suggest a role for sustained activation of B and T cells due to 
chronic local or systemic inflammation as well as chronic (auto)antigen stimulation, 
stimulating lymphocyte survival and proliferation.37    
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2.2.7 Viruses  
The Epstein-Barr virus (EBV), human T cell leukemia-lymphoma virus 1 and hepatitis C virus 
are closely associated with several types of lymphoma.39-41 The best known is EBV, found in 
close to all endemic Burkitt lymphoma, a subset of classical Hodgkin lymphomas and many 
post-transplant lymphomas.40 Orally transmitted (“kissing disease”), EBV causes a latent 
infection of B cells in most people in the world.40 In this perspective, EBV associated 
lymphomas are rare accidents of EBV colonization.40 The expression of viral proteins 
provides an anti-apoptotic function contributing to endemic Burkitt and Hodgkin 
lymphomagenesis, and drive B cell transformation in post-transplant lymphoma.40  
 
2.2.8 Immunosuppression and immunodeficiency  
The small part of the population affected by immunosuppression or immunodeficiency are 
at increased risk of malignancies, especially lymphomas. Such conditions include human 
immunodeficiency virus (HIV) infection, immunosuppressing treatment after organ 
transplant procedures and primary immunodeficiency syndromes such as primary variable 
immunodeficiency.42-44 The risk of lymphoma among HIV infected individuals used to be 75 
to 100 times that of the general population but has decreased substantially since the 
introduction of combined antiretroviral therapy.43,45 Nevertheless, increased lymphoma risk 
remains and is still the most common malignancy in this population.43 In organ transplant 
recipients, the risk of lymphoma is increased 30-50 times compared to the general 
population.45 The risk increase depends on degree and duration of immunosuppression, as 
illustrated by a higher incidence rate in heart, lung and multi-organ transplants (8-25%) than 
in kidney and liver transplants (1-5%).44 Similarly, the risk of lymphoma varies by type of 
primary immunodeficiency disorder but is generally much higher than in the general 
population (25 to several 100-fold risk increase).42 The risk increase is primarily due to 
increased risk of aggressive lymphoma subtypes.46,47 
 
The increased lymphoma risk in the context of immunosuppression and immunodeficiency 
is believed to be due to reduced immune surveillance, uncontrolled infections of oncogenic 
viruses such as EBV and chronic antigen stimulation of lymphocytes.42,43,45 Germline 
mutations in DNA repair genes may also contribute to lymphomagenesis in primary 
immunodeficiency syndromes.42   
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2.2.9 Breast implants 
Rare cases of anaplastic large cell lymphoma (ALK negative) associated with breast implants 
have recently been reported.48 Intriguingly, the vast majority of primary lymphoma of the 
breast are of B cell origin, while breast implant associated lymphomas are of T cell origin,49 
suggesting a causal role of the implant itself. The pathogenesis is not clear. The implants 
seem to cause a local chronic inflammation.48,50,51 It has been speculated that the 
inflammation is antigen-driven, with antigens derived from the implant itself or possibly 
from biofilms produced by local infection.51,52 This would in turn cause sustained T cell 
activation and in some cases formation of a T cell lymphoma.51,52  
 
2.3 CLASSIFICATION OF LYMPHOMA SUBTYPES 
Numerous classification systems have been used throughout history to define lymphoma 
subtypes.53 At the moment, we use the fourth edition of the WHO classification system of 
lymphoid malignancies published in 2008.3 A major revision is just being published, which 
will not be a fifth edition due to technical reasons, however (there are still other volumes 
pending in the fourth edition of the WHO tumor monograph series).1  
 
The cell-of-origin perspective is a major basis for the WHO classification system of 
lymphomas.3 It postulates that normal lymphocyte differentiation may get arrested at any 
stage by transformation events.29 At each stage of maturation, the normal lymphocyte 
displays characteristic cell surface markers and changes in the B or T cell receptor genes. 
These characteristics will in many aspects be retained by the malignant B or T cell 
counterpart of each stage.29 However, not all lymphoma subtypes have a clear normal 
counterpart.53 Also, a group of lymphomas corresponding to a certain cell-of-origin may 
demonstrate important differences with respect to clinical features.53 Hence, the current 
WHO classification system also takes into account clinical and genetic features when 
defining lymphoma subtypes.3  
 
The WHO classification system identifies more than forty lymphoma subtypes, of which the 
most common are shown in Figure 7.1 The subtypes are broadly categorized into Hodgkin 
lymphoma (10%), B cell lymphoma (80%) and T/NK cell lymphoma (90%), the latter two 
together often referred to as non-Hodgkin lymphoma. It is often also useful to classify B and 
T/NK cell lymphomas as indolent or aggressive.54 Indolent lymphomas grow slowly. In the 
vast majority of cases, the disease is not curable but survival is nevertheless often counted 
in many years.54 Treatment is offered upon symptoms and usually leads to temporary 
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remission.54 Aggressive lymphomas grow fast and cause death within months without 
treatment.54 With intensive treatment, however, the majority of the patients are cured.54  
 
 
Abbreviation Subtype % 
DLBCL Diffuse large B cell lymphomas 25.5 
KLL Chronic lymphocytic leukemia 24.0 
FL Follicular lymphoma 11.0 
HL, klassisk typ Hodgkin lymphoma, classical 6.5 
MCL Mantle cell lymphoma 4.2 
LPCL Lymphoplasmacytic lymphoma 4.0 
MZL Marginal zone lymphoma 3.5 
LBCL Indolent B cell lymphoma 2.3 
HBCL Aggressive B cell lymphoma 2.1 
HCL Hairy cell leukemia 1.5 
Övriga Other subtypes 15.4 
Figure 7. The ten most common lymphoma subtypes in the Swedish Lymphoma Register 
2003-2005.55  
 
2.3.1 Diffuse large B cell lymphoma 
The diffuse large B cell lymphoma subtype is investigated in Study II and IV. It is an 
aggressive lymphoma and the most common NHL subtype (Figure 7). It is a heterogeneous 
group including a number of entities differing in morphology, genetics and/or biological 
behavior, such as diffuse large B cell lymphoma not otherwise specified (including germinal 
center B cell like and activated B cell like types), primary mediastinal large B cell lymphoma, 
high grade B cell lymphoma with MYC and BCL-2 and/or BCL-6 rearrangements and T cell 
histiocyte rich large B cell lymphoma.1 They usually present with fast growing tumors in 
lymph nodes, spleen, liver, bone marrow or other organs.3 The tumor cells originate from a 
mature B cell. Morphologically, the cells are large, grow diffusely and express B cell markers 
such as CD19, CD20, CD22 and CD79a.3 Approximately 70% express the B cell 
leukemia/lymphoma (BCL) 6 oncogene.  
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2.3.2 Follicular lymphoma 
Follicular lymphoma was the focus of Study I and III and was also included among other 
subtypes in Study II and Study IV. Follicular lymphoma is one of the most common indolent 
NHL subtypes (Figure 7).3 It usually presents with enlarged lymph nodes but extranodal 
involvement, especially of the bone marrow, is common.3 Clinical behavior is variable, 
reflecting the heterogeneity of the underlying biology. The tumor cells are derived from 
germinal center B cells, both centrocytes and centroblasts. They almost always form a 
nodular growth pattern.3 The tumor cells are typically positive for CD19, CD20, CD79a, CD21 
and CD10 but lack CD5, CD43 and CD11c.3 Almost all tumor cells express HLA-DR.3 More 
than 90% carry the t(14:18) translocation, causing overexpression of the BCL-2 oncogene.3   
 
2.3.3 Chronic lymphocytic leukemia and small lymphocytic lymphoma 
Chronic lymphocytic leukemia was included in Study IV. Chronic lymphocytic leukemia and 
small lymphocytic lymphoma are different manifestations of the same disease and together 
constitute the most common type of indolent lymphoma (Figure 7). They are characterized 
by the accumulation of mature, clonal B cells in the bone marrow, blood and/or lymphoid 
organs.3 A chronic lymphocytic leukemia diagnosis requires ≥5.0 x 109 B lymphocytes/liter in 
peripheral blood with the characteristic immunophenotype CD19+, CD20+, CD23+ and 
CD5+.3 The disease is denoted small lymphocytic leukemia when the tumor cells have a 
predilection for lymphoid organs and the B lymphocyte count in the blood is <5.0 x 109. In 
this thesis, for convenience, both manifestations of the disease will be referred to as chronic 
lymphocytic leukemia.    
 
2.3.4 Mantle cell lymphoma 
Mantle cell lymphoma was studied as a separate entity in Study II and included among 
aggressive lymphomas in Study IV. Mantle cell lymphoma is a fairly uncommon subtype of 
mature B cell lymphoma, comprising 3-10% of all NHL (Figure 7).3 It is often viewed upon as 
intermediate between indolent and aggressive with regard to its biology; like indolent 
lymphomas it is incurable in the majority of cases, but has a more aggressive biology.3 
Mantle cell lymphoma usually presents with widespread lymph node involvement, often 
also engaging bone marrow and spleen.3 The malignant B cells are characterized by the 
t(11:14) translocation, causing overexpression of cyclin D1.3  
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2.3.5 T cell and NK cell lymphomas  
T/NK cell lymphomas were combined into one group in Study II and IV. T cell and NK cell 
lymphomas constitute approximately 10% of non-Hodgkin lymphomas (7% in the SCALE 
cohort, see 4.1) and form a heterogeneous group of diseases.3 Hence, each subtype of T/NK 
cell lymphoma is a rare entity with the consequence that less is known about them than the 
more common B cell subtypes. They have in common that they arise from cells of T or NK 
cell origin and, thus, (variably) express T cell markers CD3, CD2, CD5 and/or CD7 and are 
negative for B cell markers (CD19, CD20, CD23, CD79a/b).3 Most cells carry clonal T cell 
receptor rearrangements.3 They may present clinically in many different ways, depending 
on subtype. The spectrum covers everything from indolent disease of the skin, as in mucosis 
fungoides, to aggressive disease engaging lymphoid tissue as well as extranodal sites as in 
anaplastic large cell lymphoma.3  
 
2.4 PROGNOSTIC FACTORS IN NON-HODGKIN LYMPHOMA AND SUBTYPES 
When discussing prognosis of NHL, it is important to remember that it is a group of 
heterogeneous diseases, differing in biology, clinical course, response to treatment and, 
hence, prognosis.  
Several prognostic markers have been elaborated to help in patient counseling, guide 
treatment strategy and to stratify patients with NHL in clinical trials. Established prognostic 
factors differ to some extent by NHL but have in common that they are based on host 
factors (age and performance status) and disease related factors (stage, number of involved 
extranodal sites, level of lactate dehydrogenase, hemoglobin, and blood cell count).56-59 The 
prognostic factors are combined into prognostic scores that stratify patients into risk groups 
with different expected survival.56-59 However, there is still great variability in survival within 
and overlap between prognostic groups for reasons that we do not fully understand.  
Treatment influences NHL survival too. In both aggressive and indolent lymphomas, the 
treatment backbone is still single or multi-agent chemotherapy. Since the beginning of the 
millennium, the addition of the monoclonal anti-CD20 antibody rituximab results in 
important survival benefits for patients with B cell lymphomas.60-63 Radiotherapy is a local 
treatment of importance for selected patients. New small molecules targeting tyrosine 
kinases have become part of the treatment arsenal in chronic lymphocytic leukemia64 but 
not yet other subtypes.65 Immunotherapy, such as anti-CTLA4 or anti-PD1 antibodies, are 
investigational in NHL at this point.65 Therapies such as these will change the way we treat 
NHL in the near future. This may have implications not only on the prognosis but also on 
what factors are relevant for predicting survival.  
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2.4.1 Diffuse large B cell lymphoma 
First published in 1993, the international prognostic index (IPI) is still the main tool to 
stratify patients by expected prognosis.57 Recently, gene expression profile studies and 
studies of other biological factors have identified other markers of importance for 
identifying patients with good or poor prognosis.   
 
2.4.1.1 The International Prognostic Index 
Since IPI was first proposed in 1993,57 it has been re-evaluated and shown to be valid also in 
the rituximab era.66 It consists of five host and tumor related factors:  
 Age >60 years 
 Lactate dehydrogenase greater than normal  
 Eastern Cooperative Oncology Group performance status ≥2 
 Ann Arbour stage III or IV 
 Number of extra nodal sites involved ≥2 
Each factor gives one point when present. Summing up the points (0 to 5) will stratify the 
patient into a prognostic group with different expected survival (Table 2).  
 
Table 2. IPI score and corresponding risk groups. The progression-free survival (PFS) and 
overall survival (OS) estimates are from the rituximab era.66 
IPI score Risk group 3 year PFS, % 3 year OS, % 
0-1 Low 87 91 
2 Low-intermediate 75 81 
3 High-intermediate 59 65 
4-5 High 50 59 
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2.4.1.2 Cell of origin – gene expression profiles 
Recently, two subtypes of diffuse large B cell lymphoma have been identified that have 
distinct gene expression profiles that correlate with prognosis.67 The two gene expression 
patterns correspond to two different steps of normal B cell differentiation, germinal center 
B cell (GCB) and activated B cell (ABC).67 When given similar treatments, patients with the 
ABC type fare much worse than patients with GCB type (Figure 8). 
  
Figure 8, from Gutierrez-Garcia et al, Blood 2011,67 illustrating how progression-free (A) and 
overall (B) survival differed between 157 patients with diffuse large B cell lymphomas 
demonstrating gene expression patterns of either germinal center B (GCB) type or activated 
B cell (ABC) type. Reprinted with permission of ASCO 2017.  
 
2.4.1.3 MYC translocation and double hit diffuse large B cell lymphoma 
Translocations involving the c-MYC oncogene are present in 5-10% of diffuse large B cell 
lymphomas. It is an independent prognostic factor associated with worse outcome when 
present (progression-free survival hazard ratio (HR)=3.28, P=0.003, overall survival HR=2.98, 
P=0.01).68  Double hit refers to lymphomas that carry a translocation involving the c-MYC 
gene concurrently with a translocation of BCL-2 or, less commonly, BCL-6.69 The double hit 
confers a worse prognosis than a c-MYC translocation alone.69 A synergistic effect of MYC 
and BCL-2 overexpression may explain this observation.69 
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2.4.2 Follicular lymphoma 
The follicular lymphoma International Prognostic Index (FLIPI) is the main tool used to 
predict disease course in follicular lymphoma.  
2.4.2.1 Follicular Lymphoma International Prognostic Index 
FLIPI was first evaluated in the pre-rituximab era56 but has since been validated in the 
rituximab era.70 FLIPI consists of five factors that, when present in a patient, results in one 
point each: 
 Age  >60 years 
 Ann Arbor stage III or IV 
 Hemoglobin level <120 g/L 
 Number of involved nodal areas ≥5 
 Lactate dehydrogenase greater than normal  
Summing up the points (0-5), a patient is attributed to one of three risk groups with 
different prognosis: Low risk 0-1 points, intermediate risk 2 points, high risk 3-5 points 
(Figure 9) 
Figure 9, from Nooka et al, Annals of Oncology 2013,70 illustrating differences in overall 
survival among (A) all included patients and (B) among patients for whom rituximab was 
part of the treatment. Reprinted with permission of Oxford University Press.    
2.4.2.2 Tumor grade 
Follicular lymphomas are graded on a scale from 1 to 3 based on the number of centroblasts 
per high power field (grade 1: 0-5 centroblasts, grade 2: 6-15 centroblasts, grade 3: >15 
centroblasts).3 Grade 3 has been further subdivided into 3a (centrocytes are present) and 3b 
(solid sheets of centroblasts).71 The prognostic importance of tumor grade is limited, 
however. In practice grade 1 to 3a follicular lymphomas are considered indolent, whereas 
grade 3b follicular lymphomas are considered aggressive lymphomas and treated as such.     
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2.4.3 Chronic lymphocytic leukemia and small lymphocytic lymphoma 
The Rai and Binet staging systems are the most widely used prognostic tools in the clinical 
setting.58,59 Other factors used in the clinical setting are lymphocyte doubling time and 
certain genetic aberrations: deletion of 17p (del17p), deletion of 11q (del11q), trisomy 12 
and deletion of 13q (del13q). Several other factors of less or uncertain importance have 
been or are under evaluation but will not be covered in this thesis.  
 
2.4.3.1 Rai staging system 
The Rai staging system is based on the idea that chronic lymphocytic leukemia progresses 
along a somewhat predictable path, starting in the blood and bone marrow (stage 0), going 
on to involving lymph nodes (stage I), spleen and liver (stage II) and eventually lead to bone 
marrow failure (stage III and IV).59 The system was later modified to comprise three risk 
groups (low, intermediate and high) since there was no significant difference in survival 
between stage I and II and between stage III and IV. 
Rai stage Description Modified Rai Median survival in original Rai study 
0 Lymphocytosis only Low 12.5 years 
I Enlarged lymph nodes (> 1 cm) Intermediate 8.4 years 
II Enlarged liver or spleen   5.9 years 
III Anemia (hemoglobin <110 g/L High 1.6 years 
IV Thrombocytopenia (<100 x109 /L)   
 
2.4.3.2 Binet staging system 
The Binet staging system counts lymphoid sites involved (cervical, axillary and inguinal 
nodes, liver, spleen) and each site gets equal weight.58 The presence of anemia (hemoglobin 
<100 g/L) or thrombocytopenia (platelets <100 x109 /L) indicate a worse prognosis, like in 
the Rai system.  
Binet stage Description Median survival in original Binet study 
A 1 or 2 lymphoid sites involved Comparable to age-matched controls 
B ≥3 lymphoid sites involved 7 years 
C Anemia or thrombocytopenia 2 years 
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2.4.3.3 Lymphocyte doubling time 
A lymphocyte doubling time (actual or estimated) of <12 months indicate a more aggressive 
disease course and worse prognosis compared to doubling time >12 months (Figure 10).72 
 
Figure 10, from Montserrat et al, British Journal of Hematology 1986.72 The graphs shows 
the estimated survival time (left) and time to treatment (right) in chronic lymphocytic 
leukemia patient Binet stage A or B, stratified by lymphocyte doubling time. Reprinted with 
permission of John Wiley and Sons.   
 
2.4.3.4 Genetic aberrations  
The four genetic aberrations most commonly used in the clinical setting for prognostic 
prediction are (in order from worst to best prognosis): deletion of 17p, deletion of 11q, 
trisomy 12 and deletion of 13q (Figure 11).73 Mutations in the TP53 gene has similar 
influence on survival as 17p deletion.74 The prognostic value of these markers are changing 
with the arrival of new treatments. The prognosis of patients with 11q deletions has 
improved with the use of treatments like fludarabine, cyclophosphamide and rituximab.75 
With target therapies such as ibrutinib, the prognosis of patients with 17p deletions or TP53 
mutations has improved but still remain significantly worse than that of patients without 
such aberrations.76  
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Figure 11, reproduced with permission from New England Journal of Medicine,73 Copyright 
Massachusetts Medical Society. The graphs show the estimated survival curves for patients 
with either of the four genetic abnormalities 17p deletion, 11q deletion, 13q deletion or 
trisomy 12 or with a normal genotype.    
 
2.4.3.5 Chronic lymphocytic leukemia international prognostic index 
In 2016, a new prognostic score was proposed, the chronic lymphocytic leukemia 
international prognostic index (CLL-IPI).77 CLL-IPI identifies five individual risk factors of poor 
survival that are assigned different weights: 
 TP53 status (no abnormality versus 17p deletion or TP53 mutation or both) 
 IgHV unmutated  
 β2-microglobulin concentration >3.5 mg/L 
 Binet B-C or Rai I-IV 
 Age >65 years 
After summing up the points (0-10), a patient is attributed to one of four risk groups with 
different prognosis: Low risk 0-1 point, intermediate risk 2-3 points, high risk 4-6 points, very 
high risk 7-10 (Figure 12). 
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Figure 12, from the CLL-IPI study showing the estimated overall survival by CLL-IPI risk 
groups in one of the external validation cohorts, which happened to be SCALE (see 4.1).77  
Reprinted from The Lancet Oncology, Copyright 2017, with permission from Elsevier. 
 
2.4.4 Mantle cell lymphoma 
2.4.4.1 Mantle cell lymphoma international prognostic index 
The mantle cell lymphoma international prognostic index (MIPI) may be used for prognostic 
prediction of patients with newly diagnosed mantle cell lymphoma.78 It uses information on 
age, Eastern Cooperative Oncology Group (ECOG) performance status, lactate 
dehydrogenase ratio (LDH) and total white blood cell count to define three risk groups.78  
Points Age Performance status LDH value/upper normal limit ratio White blood cell count 
0 <50 0-1 <0.67 <6.7 
1 50-59  0.67-0.99 6.7-9.9 
2 60-69 2-4 1.00-1.49 10.0-14.9 
3 ≥70  ≥1.50 ≥15.0 
MIPI has been validated in a more recent study where patients were given more modern 
treatments (survival estimates shown in the table below).79 
MIPI Score Risk group 5 year OS, % 
0-3 Low 83 
4-5 Intermediate 63 
6-12 High 34 
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2.4.4.2 High proliferation rate, Ki-67 ≥ 30% 
A high proliferation rate among the tumor cells, defined as the expression of the 
proliferation marker Ki-67 in ≥30% of tumor cells, has been shown to be an independent 
prognostic marker in mantle cell lymphoma.80 A recent study suggested combining 
information on Ki-67 with MIPI for more accurate prognostic prediction (Figure 13).80 
 
Figure 13, from Hoster el al, Journal of Clinical Oncology 2016.80 Panels (A) and (B) show 
the estimated survival curves of two different cohorts of mantle cell lymphoma patients, 
each stratified by a modified MIPI score that also includes Ki-67 (using a cutoff of 30%).  
Reprinted with permission. © 2017 American Society of Clinical Oncology. All rights 
reserved 
 
2.4.5 The B cell lymphoma microenvironment and survival 
It is becoming increasingly clear that malignant B cells of different subtypes retain a 
dependence on normal cells and structures in the tumor microenvironment (reviewed by 
Scott and Gascoyne, 2014).38 Cell-cell interactions and soluble mediators such as cytokines 
and chemokines stimulate survival and proliferation.38 The ratio between malignant cells 
and normal cells differs by lymphoma subtype, as well as by degree of dependence of tumor 
cell on external signals and by the inflammatory response of the host (Figure 6, section 
2.2.4).38 Furthermore, evidence suggest that the composition of the tumor 
microenvironment also influences the prognosis of patients with B cell lymphoma. In diffuse 
large B cell lymphoma and follicular lymphoma, studies have shown a strong correlation 
between patient survival time and gene expression profiles emanating from normal cells in 
the tumor microenvironment.81,82 In follicular lymphoma, the proportion of tumor 
infiltrating T cells has also been associated with prognosis.83,84  
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2.4.6 Host factors and non-Hodgkin lymphoma survival 
The host factors age and performance status are included in all or most of the prognostic 
indexes described above. The last few years, there have been increasing interest in whether 
other host factors, including lifestyle factors, medical history and host genetic factors, could 
also hold independent prognostic information. We investigated the association between all-
cause or lymphoma-related death and selected host factors (smoking, education, obesity, 
UV radiation, autoimmune disease and family history of hematopoietic malignancy) among 
patients with NHL, diffuse large B cell lymphoma, follicular lymphoma, mantle cell 
lymphoma and T cell lymphoma in Study II. 
 
2.4.6.1 Smoking 
Except for Study II, five other studies have investigated the association of smoking with NHL 
survival (Table 3).85-89 Among the five studies, at least one of four smoking exposure 
variables used (smoking status, duration, intensity and pack-years) reached statistical 
significance in association with survival among NHL patients. Virtually all point estimates 
indicated increased risk of death irrespective of exposure measure used. One of the studies 
also performed a meta-analysis including four of the five studies.87 In the meta-analysis, 
smoking duration, intensity and pack-years but not smoking status were significantly 
associated with increased risk of death among NHL patients. The same was observed among 
follicular lymphoma patients. Leo et al was not included in the meta-analysis, and reported 
no association between smoking status and follicular lymphoma survival. Among diffuse 
large B cell lymphoma patients, survival was associated with smoking duration in one 
study88 and smoking status in another study89 but the other three studies and the meta-
analysis reported no association. Among patients with chronic lymphocytic leukemia, 
survival was associated with smoking intensity in one study85 and smoking status in another 
study,89 while a third study reported no association.88  Regarding lymphoma-specific death, 
two studies wrote in the text that the estimates for this outcome measure were very similar 
to those for all-cause death but did not show any data.85,88 Leo et al. provided data, 
however, and demonstrated an association with smoking status among patients with NHL 
overall or chronic lymphocytic leukemia but not with diffuse large B cell lymphoma or 
follicular lymphoma.89   
 
Hence, smoking seems to increase the risk of death among NHL patients and follicular 
lymphoma patients just like it does in the general population. It is interesting to note that 
the t(14:18) translocation that occur in >90% of follicular lymphoma may be more common 
among “healthy” smokers than non-smokers.90,91 Smoking is well-known to cause deadly 
lung and cardiovascular diseases in the general population,92,93 which could account for the 
 34 
excess risk of death among smoking NHL patients too. Why there would be a differences 
between the aggressive subtype diffuse large B cell lymphoma and the indolent follicular 
lymphoma is not obvious. Patients with indolent lymphomas are expected to live for years 
(>10 years in median) and will have time to die from other causes, such as smoking related 
morbidities. Possibly, smoking does not get the chance to exert its deadly effect in 
aggressive lymphoma patients since a good proportion of these (40%) will die from the 
lymphoma itself. On the other hand, patients with comorbid conditions (caused by smoking) 
may not tolerate the intensive treatment needed to cure an aggressive lymphoma very well. 
For this reason, the treating physician may give less intensive treatment, increasing the risk 
for relapse.94 Intensive treatment may also aggravate the comorbid conditions and cause 
increased risk of all-cause death.94,95         
 
2.4.6.2 Socioeconomic status 
Two previous studies from Denmark and Scotland explored the impact of socioeconomic 
status on survival among NHL patients (Table 3).96,97 The Scottish study used residential area 
as exposure measure, while the Danish study used several measures: attained education, 
cohabiting status, affiliation to work market and disposable income. Both studies found an 
increased risk of death among NHL patients with low as compared to high socioeconomic 
status, irrespective of measure used. With regard to NHL subtypes, the Danish study 
showed similar associations with all-cause death among patients with diffuse large B cell 
lymphoma and indolent lymphomas as those observed among NHL overall, although some 
estimates were not statistically significant. The Scottish study did not explore subtypes.  
 
Both studies also demonstrated that NHL patients with low socioeconomic status had 
increased risk of having B symptoms and worse performance status compared to NHL 
patients with high socioeconomic status. In the Danish cohort, patients with low 
socioeconomic status also had significantly higher risk of other poor prognosis markers, 
including Ann Arbor stage III or IV, elevated lactate dehydrogenase, and IPI ≥2.98 These 
observations indicate more advanced disease stage at diagnosis among patients with low 
socioeconomic status. A possible explanation for the higher rate of B symptoms, elevated 
lactate dehydrogenase and IPI ≥2 could be more aggressive disease biology among patients 
with low socioeconomic status. This hypothesis could make sense if exposure to 
environmental risk factors differ by residential areas or employment, and that this would 
have implications for lymphoma biology. Although there is no direct evidence of this, it is 
notable that several occupations that typically require low educational level have been 
associated with increased risk of diffuse large B cell lymphoma, follicular lymphoma, chronic 
lymphocytic leukemia and mantle cell lymphoma.6,8-10 Another possibility for the worse 
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performance status and survival observed could be due to more comorbidity due to 
smoking and/or obesity among individuals with low socioeconomic status.99  
 
2.4.6.3 Obesity  
Three studies apart from our Study II have investigated the impact of obesity on survival of 
NHL patients (Table 3).86,89,100 All three reported an increased risk of all-cause death among 
obese as compared to normal-weight NHL patients, although the association in one study 
were just borderline statistically significant.100 The estimates among patients with diffuse 
large B cell lymphoma and follicular lymphoma also indicated increased risk of death in 
association with obesity but none of the estimates reached statistical significance. Two of 
the three studies also looked at patients with chronic lymphocytic leukemia with conflicting 
results: a small study of 62 female patients found no association100 while a larger study 
including 287 patients of both sexes found an increased risk of death in association with 
obesity.89 Only one study investigated the potential impact of obesity on NHL-specific death 
and found increased risk among patients with NHL or chronic lymphocytic leukemia but not 
diffuse large B cell lymphoma or follicular lymphoma.89       
 
The impact of obesity on risk and prognosis in several cancer forms has been extensively 
studied, and was recently the focus of a series of articles in Journal of Clinical Oncology.101 
The picture observed in several common cancer forms, like prostate, breast and colon 
cancer, is similar to the one described for NHL patients above. The reason why obesity 
would confer poorer survival among patients with lymphoma or other cancers is not clear 
but several hypotheses exist. Obesity itself contribute to insulin resistance.101 This leads to 
hyperinsulinemia which stimulates increased levels of the hormone insulin-like growth 
factor-1, in turn stimulating cell growth and proliferation and inhibiting apoptosis. In the 
setting of insulin resistance, adipose tissue inflammation causes production of cytokines and 
increased levels of leptin and decreased levels of adiponectin. All these factors could 
potentially stimulate tumor growth and progression.102,103    
 
2.4.6.4 Ultraviolet radiation and vitamin D 
Two studies have investigated the impact of vitamin D level in the blood and survival among 
patients with different NHL subtypes (Table 3).104,105 I was unable to identify studies  
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Table 3. Host factors in prognosis of NHL and subtypes in previous studies. 
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exploring UV radiation, however. Neither of the two studies looked at NHL overall. The first 
study reported an association of vitamin D insufficiency with increased risk of death among 
patients with diffuse large B cell lymphoma and T cell lymphomas but not other subtypes, 
including follicular lymphoma.104 The second study included two cohorts of follicular 
lymphoma patients and analyzed them separately.105 Vitamin D insufficiency was associated 
with worse progression-free survival in both cohorts and with increased risk of all-cause 
death in one cohort, although the point estimates were above one in both cohorts. 
 
Vitamin D is despite the name not a vitamin but the precursor of the potent steroid 
hormone calcitriol.106 With adequate exposure to UV radiation, the skin produces sufficient 
amounts of vitamin D. However, for many reasons, a considerable proportion of humans 
worldwide are not adequately exposed to UV radiation and are consequently vitamin D 
deficient.106 Calcitriol exerts several anticancer effects, including inhibition of proliferation 
and increased sensitivity to apoptotic signals.106 Aberrantly high expression levels of the 
enzymes degrading calcitriol (CYP24A1 and CYP27B1) has been demonstrated in some 
cancers, a resistance mechanism that could be overcome with increased levels of vitamin D 
in the blood.106    
 
2.4.6.5 Autoimmune disease 
Three studies apart from Study II have investigated the impact of autoimmune disease on 
NHL prognosis. Two looked at RA107,108 and one on celiac disease (Table 3).109 Regarding RA, 
Mikuls et al found no association with all-cause or lymphoma-specific death but an 
increased risk of death from other causes than lymphoma. Ji et al. found a statistically 
significantly increased risk of both all-cause and lymphoma-specific death among NHL 
patients with RA compared to those without. There was no association among patients with 
diffuse large B cell lymphoma. Celiac disease was not associated with survival among NHL 
patients.109  
 
It is thus unclear whether autoimmune disease influences survival of NHL patients. There is 
data suggesting a more aggressive NHL biology in patients with RA or celiac disease, which 
would explain an excess mortality in this group compared to NHL patients without 
autoimmune disease.109,110 RA patients overall have increased risk of death compared to the 
general population, primarily due to cardiovascular disease.111 Comorbidity increases the 
risk of death in connection with chemotherapy,95 which could also explain a worse prognosis 
among RA patients with NHL.         
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2.4.6.6 Family history of hematopoietic malignancy 
Two previous studies have compared survival among lymphoma patients with a first-degree 
relative with any lymphoma112 or NHL113 to survival among sporadic cases and found no 
difference (Table 3). One of these studies also investigated concordance in survival time 
among the familial cases and found a statistically non-significant trend.113  
 
Just that fact that a NHL patient has a first-degree relative that has had lymphoma does not 
predict prognosis. A reason for this could be that genetic polymorphism within one family 
confer a better prognosis than average while genetic polymorphisms within another family 
confer a worse prognosis than average. Upon combining all familial cases, the average effect 
of the genetic polymorphisms would go towards zero. The non-significant trend in familial 
concordance of survival observed in one of the study supports this notion. So does the 
finding of both protective and deleterious SNPs in candidate gene studies, discussed next.          
 
2.4.6.7 Germline genetic polymorphisms 
We explored the potential impact of SNPs on follicular lymphoma survival in Study III. At 
least 13 previous studies have also investigated selected SNPs in selected genes (candidate 
gene studies) for their association with follicular lymphoma outcomes, of which a minority 
were statistically significant (Table 4).114-125 As shown in Table 4, few of the findings have 
been validated. Hence, although results are suggestive, there is not yet one SNP 
convincingly linked to follicular lymphoma prognosis. The rational for exploring genetic 
polymorphisms is the considerable amount of variability in outcome of patients with the 
same FLIPI. Also, as described above, gene expression in normal cells in the tumor 
microenvironment, which are govern by normal DNA, influences follicular lymphoma 
survival. Genetic polymorphisms could possibly explain these observed differences in gene 
expression.   
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Table 4. List of SNPs associated with follicular lymphoma outcome in previous studies.   
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3 HYPOTHESES AND OBJECTIVES 
3.1 HYPOTHESES 
The overall hypothesis of this thesis is centered around a potential role for host factors in 
risk as well as prognosis of NHL subtypes. More specifically, we hypothesized that: 
I. The contribution of smoking to risk of follicular lymphoma differs by the 
presence/absence of certain amino-acid variants in the HLA-DRB1 molecule. 
II. Host factors (some of which are also risk factors for NHL development) influence 
lymphoma-related and overall survival of NHL overall and/or subtypes (diffuse 
large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or T cell 
lymphoma).  
III. Germline genetic polymorphisms in the form of SNPs influence the rate of 
follicular lymphoma progression.  
IV. The prognosis of a lymphoid malignancy and/or subtypes is to some extent 
genetically inherited.  
3.2 OBJECTIVES 
By exploring these hypotheses we sought to contribute to the knowledge of what factors 
influence risk and prognosis of NHL and/or its subtypes. More specifically, the objectives of 
the four studies were: 
I. To investigate if smoking actually is a risk factor of follicular lymphoma, and if so 
only among indviduals with genetic susceptibility such as germline genetic 
polymorphisms in HLA-DRB1. This could explain the somewhat conflicting results 
of previous studies and contribute to our understanding of follicular 
lymphomagenesis.  
II. To identify readily available factors with prognostic importance that could help 
clinicians in consulting patients with a newly diagnosed NHL.    
III. To explore if variation in normal DNA (as opposed to tumor DNA) influences 
survival of follicular lymphoma patients, which could help us understand 
observed but unexplained differences in survival in this patient group.  
IV. To provide further evidence of a link between germline DNA and survival of 
lymphoid malignancies. If shown, it would support results from candidate gene 
and genome-wide associations studies that have found associations between 
different SNPs and survival of several lymphoid malignancies and encourage 
further studies of how the host constitution may affect lymphoma survival and 
how adverse effects could potentially be overcome. 
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4 DATA SOURCES 
4.1 THE SCANDINAVIAN LYMPHOMA ETIOLOGY STUDY 
Lymphoma patients and/or control subjects included in the Scandinavian Lymphoma 
Etiology (SCALE) study were used in Study I, II and III. SCALE was launched with the aim to 
study risk factors of lymphoma to gain knowledge on lymphoma etiology and understand 
the increase of lymphoma incidence in the precedent decades. SCALE included adult (≥18 
years of age) patients with incident lymphoma between 1999 and 2002 and covered the 
whole of Sweden and Denmark.17 Patients were identified through a network of physicians 
working with lymphoma patients. There was also a backup system that identified new 
lymphoma diagnoses reported from all pathology and cytology units in Sweden and 
Denmark. Upon inclusion, the tumor material was reviewed by hematopathologists and 
classified according to the 2001 WHO classification system.126 Control subjects were 
randomly sampled from national population register in Sweden and Denmark every six 
months between 1999 and 2002, and were frequency matched on the expected number of 
new lymphoma patients in each country, by age and sex. Study subjects were excluded if 
they had a history of organ transplantation, HIV infection or other hematopoietic 
malignancy, or did not speak Swedish or Danish well enough to respond to a questionnaire 
(see below). Patients and control subjects had to give their informed consent. Of 4506 
eligible lymphoma patients, 3740 (83%) were included in the study (case patients). The 
corresponding numbers for control subjects were 4489 and 3187 (71%). Among the case 
patients, 3055 (82%) had NHL (796 diffuse large B cell lymphoma, 752 chronic lymphocytic 
leukemia, 586 follicular lymphoma, 678 other B cell lymphomas, 204 T cell lymphomas). 
Demographic data and information on potential risk factors were gathered through 
telephone interviews using computer-aided questionnaires. The majority (80%) were 
interviewed within three months from diagnosis/study inclusion (range 0-40 months). Of 
those interviewed, the majority of case patients (2790, 91%) and control subjects (2118, 
66%) also gave blood.127 Genotyping of approximately 300 000 SNPs were performed on a 
subset of lymphoma cases and controls at the Genome Institute of Singapore (see 5.6 for 
details).128  
 
As years have passed, the case patient cohort has also been possible to use for prognostic 
studies, with the limitation that most patients have not received primary treatment that 
included rituximab (about 10% in Swedish SCALE).129 Clinical data has been collected for 
Swedish patients from medical records, including information on lymphoma stage, 
performance status, comorbidity, hemoglobin and lactate dehydrogenase levels, treatments 
and recurrent disease. For Danish patients, data on lymphoma stage, performance status, 
treatment and follow-up was obtained from the Danish national lymphoma register LYFO.130     
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4.2 THE EPIDEMIOLOGICAL INVESTIGATION OF RHEUMATOID ARTHRITIS 
STUDY 
For Study III, we used 676 Swedish control subjects included in the population-based 
Epidemiological Investigation of Rheumatoid Arthritis (EIRA) case-control study between 
1999 and 2003.131 EIRA is an ongoing case-control study of the autoimmune disease 
rheumatoid arthritis, recruiting cases and controls since 1996. The control subjects were 
randomly selected from the Swedish national population register and matched with regard 
to the rheumatoid arthritis patients’ age, sex and residential area. All study subjects gave 
informed consent. Demographic data and information on potential risk factors of 
rheumatoid arthritis (including smoking) were gathered by questionnaires sent by mail. 
Blood samples were obtained from 58% of control subjects that had first responded to the 
questionnaire. As in the SCALE study, SNP genotyping was done at the Genome Institute of 
Singapore.   
 
4.3 THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO COHORT 
We used 213 follicular lymphoma cases with European ancestry from the University of 
California San Francisco (UCSF) case-control study of lymphoma for Study II. UCSF included 
incident NHL patients aged 20-84 in the San Francisco Bay area 2001-2006.132 Patients were 
identified through a rapid case ascertainment system by the Cancer Prevention Institute of 
California with case reporting supplemented by Surveillance, Epidemiology and End Results 
data. All study subjects gave informed consent. Of eligible cases 69% were included. Blood 
or buccal specimens for DNA preparation were obtained from a majority (87%) of cases a 
median 27 days after diagnosis. Genotype data of approximately 300 000 SNPs were 
available for 213 follicular lymphoma patients (see 5.6 for details).  
  
4.4 SWEDISH NATIONAL REGISTERS 
4.4.1 The Cancer register 
The Swedish Cancer register is kept by the National Board of Health and Welfare. The 
register includes incident malignant diseases (and some benign tumors) of Swedish 
residents since 1958.133 All physicians in Sweden are obliged by National Board of Health 
and Welfare regulations to report all new malignant tumors to the register. In addition, 
pathologists and cytologists also have to report every malignant tumor diagnosed at their 
units. This system ensures completeness and reliability, both of which were estimated to be 
close to 100% in the late 1970s and in 1998.134,135 For each case, the register keeps record of 
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personal identification number, sex, age and date of diagnosis, and type of malignancy 
stored as International Classification of Disease (ICD) codes, seventh version. Since 1993, 
histopathologic type is also recorded as Systematized Nomenclature of Medicine (SNOMED) 
codes.133   
 
4.4.2 The Cause of Death register 
The Swedish Cause of Death register is kept by Statistics Sweden. The register in its present 
form keeps record of the date and cause of all deaths of all Swedish residents from 1961.136 
An older version of the register keeps the same information between 1952 and 1960. The 
date and conditions related to the death are reported to the register on a death certificate 
issued by the physician that verifies the death. Statistics Sweden assigns ICD codes to the 
conditions reported on the certificate and selects a single main underlying cause of death as 
defined by the WHO in the current ICD version (ICD-6 1952-1957, ICD-7 1958-1968, ICD-8 
1969-1986, ICD-9 1987-1996, ICD-10 1997- still in use). The register is complete with regard 
to capturing all deaths along with the date.136 With regard to the cause of death, it is not as 
straightforward. The validity of the cause of death reported on the death certificate 
depends on how well the physician examined the circumstances of the death. This could 
vary from an educated guess based on information from relatives to a full forensic 
investigation.137 A validation study compared the cause of death stated on death certificates 
with the main diagnosis of hospital discharge records in deaths occurring 1995.138 The 
correlation was greater for deaths occurring in hospitals than at home, and for deaths 
resulting from an emergency condition rather than a chronic one.138 The best agreement 
was observed for malignant neoplasms (90-98%).138 Another problem is that the WHO rules 
and guidelines on coding and classification of cause of death have developed over a long 
period of time and have been subject to changes and sometimes open to different 
interpretations.137 Furthermore, the underlying cause of death concept has become more 
difficult to apply as we live longer and often have time to accumulate multiple potentially 
fatal condition.137 This makes the validity of comparisons made over long time periods 
uncertain.       
 
4.4.3 The Total Population register 
The Total Population register is maintained by Statistics Sweden and was founded 1968, 
when a large part of available Swedish population data was computerized 139 At that time, 
personal records with demographic information were kept by Church of Sweden. This duty 
was taken over by the Swedish Tax Agency 1 July 1991. The Total Population register 
includes all individuals that resided (Swedish: folkbokförda) in Sweden at some point since 
1968. There is a Total Population register for each year since 1968. The register also includes 
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selected individual level historical data for longitudinal studies. The Total Population register 
contains information on life events, including birth, death, emigration and immigration, as 
well as sex and family relations. The coverage is virtually 100% for births and deaths, 95% for 
immigration and 91% for emigration. An older version of the Total Population register keeps 
record of births and deaths from 1961 through 1997.       
 
4.4.4 The Multi-generation register 
The Multi-generation register is kept by Statistics Sweden.140 To be included, an individual 
must have been born in 1932 or later and registered as resident in Sweden at some point 
since 1961. These individuals are defined as index persons. The identities of the index 
persons’ biological parents are collected from birth certificates and recorded in the register. 
Married couples are automatically stated as the biological parents on the birth certificate. 
For unmarried couples, fatherhood is certified by the couple at a visit to the Social Welfare 
Committee shortly after birth. The registered parent-index person relations are used to 
derive biological sisters and brothers, as well as half-siblings. In the case of adoption, this is 
also recorded in the register. The completeness varies over time and by whether the index 
person was born in Sweden or not. As illustrated by Figure 14, the coverage of biological 
mothers and fathers is close to complete for individuals who were alive 1 July 1991 and born 
in Sweden. For index persons born outside of Sweden, data is much less complete. Also, 
parental information is missing for a large number of index persons who died 30 June 1991 
or before, as illustrated by Figure 15. The reason for this is that the personal records of 
these individuals were not computerized when the Swedish Tax Agency took over the 
responsibility from Church of Sweden 1 July 1991. Work of adding data on these individuals 
is ongoing.    
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Figure 14, from a report by Statistics Sweden on the Multi-generation register 2012.140 The 
graph shows that the coverage of biological parents of index persons alive 1 July 1991 and 
born in or outside of Sweden, by calendar year of birth of index persons.    
 
 
Figure 15, from a report by Statistics Sweden on the Multi-generation register 2012.140 The 
graph shows the proportion of individuals with information on their biological parents 
among persons deceased 1961-2012, when measured in the register the year 2000 and 
2012, by calendar year of death of the index persons. The increase in coverage between 
2000 and 2012 is thanks to ongoing work to supplement data for index persons deceased 30 
June 1991 or before.  
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4.4.5 Census records 
Censuses were performed in Sweden every fifth year between 1960 and 1990, and the 
records are kept by Statistics Sweden.141 The censuses covered all individuals registered as 
residents in Sweden at the time of each census. Information was collected by questionnaires 
sent by mail and to some extent from available registers. The data collected varied 
somewhat between censuses but always included individual level information on 
demographic variables and employment. Based on employment, a socioeconomic index 
(SEI) was created and included in all censuses except in 1975. Attained educational level was 
included in the censuses of 1960, 1970 and 1990. Quality controls were performed upon 
each census and the coverage and completeness were reported to be very good. Detailed 
information on each census is available at Statistics Sweden (http://www.scb.se/sv_/Hitta-
statistik/Historisk-statistik/Digitaliserat---Statistik-efter-serie/Sveriges-officiella-statistik-
SOS-utg-1912-/Folk--och-bostadsrakningarna-1860-1990/Folk--och-bostadsrakningen-1965-
1990/).  
 
4.4.6 The Longitudinal Integration database for health insurance and labor 
market studies (LISA) 
The Longitudinal Integration database for health insurance and labor market studies (LISA) is 
maintained by Statistics Sweden.141 The database holds annual registers since 1990. LISA 
includes all individuals 15 years of age or older (16 years or older before 2010) that were 
registered as residents in Sweden 31 December each year. Data is collected from several 
national registers of high coverage and quality. For each individual, detailed socioeconomic 
data is available, including employment and level of attained education.  The completeness 
and validity of the data in LISA is dependent on the quality of each register from where the 
data was obtained. Missing data regarding education level was observed in 1.7% of 
individuals 25-64 years of age in LISA 2013.142 The same number in 1990 was 1.9% for 
individuals 16-64 years of age. The majority of those missing data were born outside of 
Sweden. In 2002 validation of the Education register, from which data on education level is 
collected, was done. Misclassification of education level was uncommon (1%) among 
individuals with high level of education (>12 years), 16% among individuals with 
intermediate level (10-12 years) and 77% among those low level of education (9 years of 
less).143 Typically, misclassified individuals should be moved up one level (Table 5). 
 
 
 
  
  49 
Table 5. Proportion (%) of individuals with misclassified education level in LISA 2002 (based 
on data from the Education register).  
Education  Validation study 
register  High school  High school  University  University Research  
 ≤9 years ≤2 years 3 years <3 years ≥3 years level Total (%) 
≤9 years 77 16 5 1 1 0 100 
High school  
≤2 years 
0 88 9 2 1 0 100 
High school  
3 years 
0 0 84 13 3 0 100 
University  
<3 years 
0 0 0 89 11 0 100 
University 
≥3 years 
0 0 0 1 99 0 100 
Research 
level 
0 0 0 0 0 100 100 
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5 METHODS AND STATISTICS 
 
5.1 CASE-CONTROL STUDY DESIGN  
A case-control study design was used in Study I (Table 6). 
 
The case-control study design starts out from the outcome of interest. Step one is to identify 
all the individuals that have experienced the outcome of interest in the population under 
study (the source population). Next, control subjects that have not experienced the 
outcome are randomly sampled from the source population of the cases. The prevalence of 
the exposure of interest in the control sample should mirror that of the source population. 
Information on risk factors of interest and possible confounding factors are collected for 
cases and control subjects. Ultimately, the relative risk between cases and controls are 
calculated as odds ratios. What is actually calculated is the odds ratio of being exposed 
among cases versus controls. However, it can be shown that the odds ratio of being exposed 
equals the odds ratio of experiencing the outcome.  
 
The sampling of controls can be done in different ways and has implications for how the 
odds ratio can be interpreted (Figure 16). 
a. Case-noncase sampling. The control subjects are randomly sampled from the source 
population such that they are free from the outcome at the end of follow-up (time 
point a in Figure 16). An individual can thus not be both a case and control.  
b. Incidence density sampling (time-matched sampling). Control subjects are randomly 
sampled from the source population every time a new case arises (time point b in 
Figure 16). In this way, an individual selected as control subject may later become a 
case.  
c. Case-cohort sampling. The control subjects are randomly sampled from the whole 
source populaton, including the case patients, at the beginning of follow-up (time 
point c in Figure 16). With this design, an individual may work as both control subject 
and case.   
 
Depending on sampling scheme used, the odds ratio will estimate either a risk ratio 
(sampling scheme c), odds ratio (sample scheme a) or incidence rate ratio (sampling scheme 
b).  
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Figure 16 illustrates the different time points at which control sampling can be done in case-
control studies.  
 
 
5.2 COHORT STUDY DESIGN  
A cohort study design was used in Study II, III and IV (Table 6).  
 
The cohort study design starts out from the risk factor (exposure) of interest. Individuals 
that fulfill eligibility criteria and are free of the outcome of interest are selected to the study 
cohort. The exposures as well as possible confounders are measured for each study subject. 
Next, the study subjects are followed over time until they have experienced the outcome, 
are lost to follow-up or until the termination of the study. This design could also be termed 
internal cohort study as opposed to an external cohort study where an external group is 
used for comparison. Data for cohort studies can also be obtained from pre-existing national 
registers, some of which are described in section 4.1.4. This was the case in Study IV. The 
advantages of using these registers are that they are population based and aim to include all 
Swedish residents (no selection). Linkage with several national registers may provide a wide 
range of data. They usually span over a long period of time, allowing for longitudinal studies. 
Without this kind of data, studies like Study IV would be difficult to do. The major drawback 
of using national registers is the lack of clinical data. 
 
 52 
5.3 STATISTICS  
5.3.1 The Kaplan-Meier estimator  
We used the Kaplan-Meier estimator144 in Study II with the aim to illustrate differences in 
survival by smoking status in patients with NHL. The method uses all available observations, 
both those that have experienced the outcome and those that have not (censored 
observations). It is important to keep in mind that the Kaplan-Meier estimator provides 
univariate estimates. That is, the estimates are not adjusted for possible confounders and 
will therefore be more or less biased in an observational study.   
 
The Kaplan-Meier estimator makes one assumption to be aware of, namely that the reason 
for the censoring is independent of the outcome, i.e. that the censoring is non-informative.  
 
5.3.2 Cox proportional hazards regression  
We used Cox proportional hazards regression models145 to estimate the relative mortality 
rates (hazard ratios) by the risk factors of interest, such as smoking status (Study II), SNP 
alleles (Study III) or the survival of a first-degree relative (Study IV).  
 
While the Kaplan-Meier method estimates the probability of staying alive over time (the 
survival function), Cox regression estimates the risk of dying over time (the hazard function). 
The advantage with Cox regression is that it allows estimation of the hazard ratio for a risk 
factor of interest while simultaneously accounting for the effect of other variables, such as 
confounders. Cox regression is also possible to use on censored data. A drawback is that it 
only estimates hazard ratios and not the baseline hazard for each risk group.  
 
Cox regression make the assumption that hazard ratios, comparing the risk groups under 
study, are constant during follow-up – the proportional hazards assumption. If the 
assumption does not hold, the resulting ratio estimates may not be valid. Two ways of 
testing the assumption are: 1) introducing interaction variables between the risk factor(s) 
and a variable that represents the underlying time scale in the Cox model (which allows the 
effect of the risk factor to vary with time), and 2) plotting the Schoenfeld residuals from the 
Cox regression models against the time scale and test if the magnitude of the residuals 
depend on time (Grambsch-Therneau test).  
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5.3.3 Competing risk regression models 
In Study II, we assessed the risk of lymphoma-related death in a competing risks regression 
model.146 Competing risks are present when two (or more) events are linked such that the 
occurrence of one event either precludes or alters the probability of the other event to take 
place. In ordinary Cox regression models, competing events are censored and the 
observation removed from the risk set when the competing event occurs. It thus treats the 
competing event as if it was not possible to take place. In competing risks regression, 
individuals experiencing the competing event remain in the risk set, although their 
contribution is mitigated by calculated weights (the size determined by the degree of 
dependence of the two competing events). The resulting hazard of each event (the one of 
interest and the competing one) is estimated (subdistribution hazard). The subdistribution 
hazard of the competing event is taken into account when estimating the subdistribution 
hazard of the outcome of interest.     
 
The interpretation of the HR of the two models become somewhat different. Under certain 
assumptions, the hazard ratios obtained from Cox regression models provide an estimate of 
the relative risk of the outcome (given different levels of exposure) in the hypothetical 
situation where the competing event does not exist. In competing risks regressions, the 
subdistribution HR has a less intuitive interpretation since individuals who have experienced 
the competing event remain in the risk set. However, significant differences in the 
subdistribution hazards suggest that the absolute risk of experiencing the event (in the real 
world where competing events exist) differs by risk group.   
 
5.3.4 Logistic regression  
We used logistic regression models in Study I, when examining the possible interaction 
between smoking status and HLA-DRB1 variation in risk of follicular lymphoma.  
 
Logistic regression is appropriate for dichotomous outcomes. The risk factor of interest and 
confounders included in the model on the other hand may be continuous or categorical. 
Logistic regression estimates the relative risk of the outcome in different risk groups as odds 
ratios. There is no time scale in logistic regression, making reversed causality a possibility.  
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5.3.5 Analysis of interaction 
We performed an analysis of interaction between smoking status and HLA-DRB1 haplotypes 
in risk of follicular lymphoma in Study I.  
 
By interaction one could mean statistical interaction between two covariates in a statistical 
model with the purpose to allow more flexibility in the model. Our purpose was to 
investigate potential biological interaction between two factors in the pathogenesis of 
follicular lymphoma, however. An issue that could be debated is how interaction is best 
measured: on the multiplicative (risk ratio) or additive (risk difference) scale? Most studies 
report interaction on the multiplicative scale.147 Some statisticians have argued, however, 
that its frequent use may be due to convenience rather than consideration about what 
measure is most preferable, since standard statistical software will automatically give 
confidence intervals for multiplicative interactions while additional work is needed to obtain 
measures on the additive scale.148 The additive scale may be preferred for the following 
reasons:148 
 The additive scale is of more value from a public health perspective, since it may 
help distinguish the groups that would benefit the most from an intervention.  
 The additive scale seems to better reflect a biological synergism than does the 
multiplicative scale. 
 
Furthermore, it can be shown that if each of two exposures under investigation are 
associated with the outcome, there will be interaction on some scale.149 It thus seems 
important to pick scale before starting analysis. Given these arguments and experience from 
studies of smoking and HLA variation in risk of RA, we chose the additive scale for our 
analyses of interaction. Consequently, in Study I, interaction was defined as a joint effect of 
smoking status and amino-acid haplotype combination on follicular lymphoma risk that 
differed from the sum of the effect of each factor alone (deviation from additivity of 
effects), as recommended by Rothman et al.150 Interaction was assessed by estimating the 
proportion of the joint effect that could be attributed to the interaction itself, the 
attributable proportion (AP) with 95% confidence intervals, as described by Hosmer and 
Lemeshow.151  
AP was calculated by subtracting the relative risk (RR) of follicular lymphoma for current 
relative to never smoking (RR(AB̅)) and two amino-acid haplotype alleles relative to no 
allele (RR(A̅B)) from the joint effect of the two risk factors relative to having no risk factors 
(RR(AB)) and then dividing the difference with the joint effect of the two risk factors 
(RR(AB)):  
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 𝐴𝑃 =
𝑅𝑅(𝐴𝐵)−𝑅𝑅(𝐴B̅)−𝑅𝑅(A̅𝐵)+1
𝑅𝑅(𝐴𝐵)
 
Where A= presence of current smoking, B= presence of two risk haplotype alleles, A̅= 
absence of current smoking (i.e. never smoking), B̅= absence of two risk haplotype alleles 
(i.e. no risk allele).  
 
5.3.6 The DerSimonian-Laird method for pooling results 
In Study III, we wanted to weigh together results from two independent GWAS (SCALE and 
UCSF, see 4.1 and 4.3 for details regarding these cohorts). The aim was to strengthen the 
possibility to demonstrate a possible association between investigated SNPs with follicular 
lymphoma outcome. For this, we used a random effects model described by DerSimonian 
and Laird in 1986.152   
 
The difficulty in combining results from different studies is that they may differ in study 
design, population characteristics and sampling errors. A fixed effects model assumes that 
the different studies actually estimate the same true effect of the risk factor of interest on 
an outcome.153 Then, different results that may be observed between studies are only due 
to chance. The random effects model on the other hand assumes that the different studies 
are in fact estimating different but closely related true effects of the risk factor on the 
outcome.  
 
The DerSimonian-Laird method considers the difficulties in combining results from different 
studies by 1) calculating weights for each study based on the amount of information they 
provide, and 2) including an estimated value of the heterogeneity of effects between the 
studies in the analysis. Large studies will get more weight than small studies and will thus 
influence the final estimate more. The greater the estimated heterogeneity between 
studies, the wider the confidence interval around the estimated average effect will be. 
 
We chose a random effects model for pooling the estimates in the two GWAS because we 
reasoned that this model may better reflect our lack of knowledge of the possible true 
nature that the investigated SNPs may have on lymphoma progression as compared to a fix 
effects model. Although the UCSF cohort was of European ancestry and we accounted for 
population stratification both in UCSF and SCALE, there may still be a difference in the true 
effect between the two populations that is not due to chance.   
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5.4 Study I: Possible interaction between cigarette smoking and human 
leukocyte antigen DRB1 variation in risk of follicular lymphoma 
We used 373 Swedish and Danish incident follicular lymphoma patients and 142 Danish 
control subjects included in SCALE 1999-2002 (see 4.1; Table 6). Swedish SCALE control 
subjects could not be used since DNA was not available for this group. Instead, we used 676 
Swedish control subjects included in EIRA 1999-2003 (see 4.2). Information on smoking 
habits was collected by questionnaires by telephone in SCALE and sent by mail in EIRA soon 
after inclusion in each study. Information on amino-acids at positions 11, 13, 28, 30 and 70-
74 in HLA-DRB1 was obtained by imputation based on genome-wide SNP data in both SCALE 
(see 5.4) and EIRA. First, dense imputation of SNPs across the HLA region was done. In this 
step, the accuracy of imputation was tested by direct DNA sequencing in a subset of the 
study subjects and was found to be high (>98% allelic concordance). In the next step, the 
imputed SNP data was used to derive amino-acid data at each position of the HLA-DRB1 
molecule. Ever smoking was defined as daily smoking for at least one year. Smoking status 
was categorized as current (subject smoked at or had quit <1 year before 
diagnosis/inclusion), former (subject quit smoking ≥1 year before diagnosis/inclusion) or 
never smoker. Amino-acid positions 11, 13, 28 and 30 are linked, why we combined them 
into haplotypes (in total sixteen haplotypes were identified). We further identified the 
number of shared epitope alleles (amino-acid positions 70-74) carried by each individual. 
Shared epitope was defined as HLA-DRB1*01, HLA-DRB1*04 or HLA-DRB1*10, excluding 
HLA-DRB1*0103, HLA-DRB1*0402 and HLA-DRB1*0403 when 4-digit HLA type data was 
available. The follicular lymphoma diagnosis (outcome) was verified by hematopathologists 
upon NHL diagnosis (see 4.1 for details). We first estimated the main effects of smoking 
status and amino-acid haplotypes on follicular lymphoma risk separately using logistic 
regression models, adjusting for sex, age at diagnosis and country of residence (Sweden or 
Denmark). Amino-acid haplotypes most statistically significantly (P for trend <5.0 x10-4) 
associated with follicular lymphoma risk were brought forward for interaction analysis with 
smoking status. Interaction between smoking status and amino-acid haplotypes in the risk 
of follicular lymphoma was assessed on the additive scale, as described above (5.3.6).       
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Table 6. Study I-IV at a glance. *Although exposures of interest, these variables were also 
considered as confounders for the other exposures and thus included in all Cox models.  
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5.5 Study II: Lifestyle factors, autoimmune disease and family history in 
prognosis of non-Hodgkin lymphoma overall and subtypes 
We used a cohort of 1523 Swedish NHL patients included in SCALE 1999-2002 (see 4.1; 
Table 6). Patients with chronic lymphocytic leukemia were excluded from this study. Six 
factors were investigated for their association with all-cause and lymphoma-related death 
among all NHL patients or patients with diffuse large B cell lymphoma, follicular lymphoma, 
mantle cell lymphoma or T cell lymphomas: smoking status, education (as proxy for 
socioeconomic status), body mass index (BMI), sunbathing habits 5-10 years before 
diagnosis (as proxy for UV radiation exposure), autoimmune disease and family history of a 
hematopoietic malignancy.  
 
Information on smoking status, education, BMI, sunbathing habits and autoimmune disease 
was collected using questionnaires by telephone interviews soon after inclusion in SCALE. 
Data on family history of a hematopoietic malignancy was obtained from the Multi-
generation and Cancer register (see 4.4.4 and 4.4.1). First, first-degree relatives of the NHL 
patients were identified by linking to the Multi-generation register. Second, first-degree 
relatives with a hematopoietic malignancy were identified by linkage to the Cancer register. 
Data on the confounding factors Ann Arbor stage and extranodal disease were obtained for 
89% of NHL patients from the national Swedish lymphoma quality registers.154 Smoking 
status was defined as described on the previous page (p. 56). We further categorized 
smoking duration (1-19, 20-39 or ≥40 years), smoking intensity (1-9, 10-19 or ≥20 cigarettes 
per day) and cigarette-years (none, <200, 200-399 or ≥400 cigarette-years). We also 
categorized attained education (≤9, 10-12 or >12 years), BMI (<25, 25-29 or ≥30 kg/m2) and 
summer sunbathing frequency in the past 5-10 years before diagnosis (never, 1, 2-3 or ≥4 
times per week). Autoimmune disease was a composite variable consisting of self-reported 
physician-made diagnosis of RA (64%), SLE (7%), celiac disease (20%) or primary Sjögrens 
syndrome (10%) categorized as either present or absent. Ann Arbor stage and extranodal 
disease were combined in one variable (Ann Arbor stage 1-2, stage 2-3 or extranodal 
disease).  
 
Outcome data was obtained from the Cause-of death register (see 4.4.2) through 1 October 
2010. Lymphoma-related death was defined as having lymphoma as the main underlying or 
contributory cause of death in the Cause of Death register. Time was counted from 
diagnosis of NHL until death or end of follow-up (outcome all-cause death) or from diagnosis 
of NHL until death from lymphoma-related causes or death from other causes or end of 
follow-up (outcome lymphoma-related death). The relative risk of each potential prognostic 
factor on the two outcome measures were estimated as hazard ratios (HR) along with 95% 
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confidence intervals (CI), using Cox proportional hazard models. All Cox models were 
adjusted for sex, age at diagnosis and stage/extranodal disease. All Cox models also included 
the potential prognostic factors smoking status, education and BMI, because they were 
hypothesized to be confounders of each other as well as the other factors under study. The 
variables sunbathing, autoimmune disease and family history of hematopoietic malignancy 
were added to the Cox model individually. The proportional hazard assumption was tested 
by creating interaction variables by multiplying each potential prognostic factor with time 
and including them in the Cox models. In a sensitivity analysis, the potential bias due to 
competing risks between lymphoma-related and non-lymphoma-related deaths (when 
analyzing lymphoma-related death) was assessed in a competing risks regression model.     
 
 
5.6 Study III: A comprehensive evaluation of the role of genetic variation in 
follicular lymphoma survival 
For this study, we used 373 follicular lymphoma patients from SCALE (both Swedish and 
Danish part; see 4.1) and 213 from UCSF (see 4.3; Table 6).  
 
In SCALE, 400 follicular lymphoma patients were genotyped for 317 503 SNPs across the 
genome at the Genome Institute of Singapore. For this, the Illumina HumanHap 300 array 
(version 1.0; Illumina, Sand Diego, California, USA) was used. Individual SNPs were filtered 
out on the basis of SNP genotyping call rates (≥95%), sample completion rate (≥90%), minor 
allele frequency (MAF, ≥0.03) and non-deviation from Hardy-Weinberg equilibrium (P <10-6). 
SNPs were further excluded if there was cluster plot problems or they were located on the X 
or Y chromosome. Follicular lymphoma patients were excluded if there were gender 
discrepancies, labeling errors and/or cryptic family relations as indicated by the genome 
command in PLINK.155 Finally, population outliers were identified and removed on the basis 
of the first three principal components, computed using EIGENSTRAT in R.156 After this 
filtering process, 373 follicular lymphoma patients and 298 198 SNPs were available for 
analyses in SCALE.  
One part of the study was to test SNPs reported to be associated with follicular lymphoma 
prognosis in other studies for lymphoma-specific survival and progression in the SCALE 
cohort. These SNPs were identified by searching PubMed. Few identified SNPs were on the 
HumanHap 300 array, however. Instead we imputed the values for these SNPs in SCALE, 
using available SNP genotype data in the dataset and the 1000 Genomes Projects multi-
ethnic reference panel and Impute 2.157,158 A strict threshold was set to genotypes with 
probabilities >0.9, SNPs with information score >0.8 and call rates >0.9.   
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In the Swedish part of SCALE, we also collected information on Ann Arbor stage, 
performance status, number of involved nodal areas, hemoglobin and lactate 
dehydrogenase levels, treatment and signs of progression from medical records. Follow-up 
data was obtained from the Cause of Death register (see 4.4.2). In the Danish part of SCALE, 
information on Ann Arbor stage, performance status and vital status was collected from the 
Danish National lymphoma register LYFO.130  
 
In UCSF, >370 000 SNPs were genotypes using the Illumina HumanCNV370-Duo BeadChip 
(Illumina, Sand Diego, California, USA). After a similar filtration process as described for 
SCALE, 213 follicular lymphoma patient and 339 528 SNPs were available for analysis in 
UCSF. Population stratification was assessed using multidimensional scaling in PLINK. 
Follow-up data was obtained from the Greater Bay Area Cancer registry.  
 
Lymphoma-specific death was defined as having lymphoma as the main underlying cause of 
death. Lymphoma progression (Swedish SCALE only) was defined as start of first-line 
treatment in patients with an initial watch-and-wait strategy >6 months after diagnosis, 
start of second-line treatment in patients where first-line treatment was initiated ≤6 months 
after diagnosis, or lymphoma-specific death among these patients if no treatment was 
given. Time was counted from date of diagnosis until outcome, competing event (which was 
censored) or end of follow-up (2 February 2012 in SCALE Sweden, 17 December 2009 in 
SCALE Denmark, 31 August 2012 in UCSF).  
 
We used Cox proportional hazards regression models to estimate the relative risk of the 
outcomes by number of alleles of each SNP (0, 1 or 2). We assumed an additive model and 
treated the SNP variable as ordinal in the Cox model. All Cox models were adjusted for sex, 
age at diagnosis and population stratification (using the first three principal components). 
The results of the two GWAS (SCALE and UCSF) were pooled using a random effects model 
(see 5.3.6). Upon assessing lymphoma progression (SCALE Sweden) we tested the 
proportional hazards assumption by plotting Schoenfeld residuals against time. In 
complementary analyses of lymphoma progression, models were also adjusted for FLIPI risk 
groups and first-line rituximab.  
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5.7 Study IV: Concordance in survival of first-degree relatives diagnosed 
with a lymphoid malignancy 
 
For Study IV we use 1701 pairs of first-degree relatives with a lymphoid malignancy 
identified by linkage of the Cancer register (see 4.4.1) and the Multi-generation register (see 
4.4.4; Table 6). We first identified all individuals diagnosed with a lymphoid malignancy in 
the Cancer register 1958-2011 (Figure 17). These individuals were linked to the Multi-
generation register to identify their parents and siblings. Ultimately, 39 608 patients with 
data on first-degree relatives were identified. Among these, we identified families with two 
(N=1606), three (N=86) of four (N=9) first-degree relatives with a lymphoid malignancy. 
Among these, we defined index cases as the individual within a family that last was 
diagnosed with a lymphoid malignancy. Because data on parents are incomplete in the 
Multi-generation register for individuals that died before 1991 (see 4.4.4), only index 
patients alive in 1991 were used in the study. In families with three or four members with a 
lymphoid malignancy, we allowed two or three index cases, respectively. Hence, in a family 
with three members, two pairs of index case and first-degree relative were formed: pair 1. 
the individual diagnosed with a lymphoid malignancy last (index) and the one diagnosed 
second to last (first-degree relative), pair 2. the individual diagnosed second to last (index) 
and the one diagnosed first (first-degree relative). We formed 1701 pairs of index cases and 
first-degree relative cases in this way. Among these, 491 pairs had the same type of 
lymphoid malignancy.  
 
 
  
 
Figure 17. Illustration of the different registers used (yellow circles) and the three cohorts 
formed (orange circles).  
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Details on type of lymphoid malignancy increased with time, especially after 1993 when 
SNOMED codes were included in the Cancer Register. Due to less detail before 1993 and 
because of few observations for most subtypes, we categorized all patients (39 608) into 
seven main groups: aggressive lymphoma, indolent lymphoma, Hodgkin lymphoma, chronic 
lymphocytic leukemia, plasma cell malignancies, acute lymphoblastic leukemia and 
lymphoma unspecified (see Supplement in connection to the original paper at the end for 
details). To be able to adjust for socioeconomic status, information on attained education or 
employment (if education was not available) was obtained from the National Population 
and Housing censuses 1960, 1970, 1980 and 1990 (see 4.4.5) and the LISA database (see 
4.4.6). Statistics Sweden have defined the level of education normally needed for each type 
of employment. Using this information, we were able to define high (>12 years of 
education), intermediate (10-12 years) or low (≤9 years) socioeconomic status.  
 
Our outcome measure was all-cause death. This data and migration data was obtained from 
the Total Population register (see 4.4.3).  
 
The exposure of interest among the index cases was the survival time of their first-degree 
relative, categorized as good, expected or poor. To do this, we first had to define good, 
expected and poor survival. Our first step was thus to run a Cox proportional hazard model 
in which we included all 39 608 patients with a lymphoid malignancy minus the index cases. 
Covariates in the Cox model were sex, age and year of diagnosis and socioeconomic status, 
and it was stratified by type of lymphoid malignancy (seven levels). Time was counted from 
diagnosis until death from any cause, emigration or end of follow-up (17 June 2013). The 
deviance residuals from this Cox model provided adjusted measures of the survival time of 
each individual included. Within each type of malignancy (seven levels), we defined good, 
expected or poor survival as quartiles of deviance residuals: good survival was define as the 
quartile of deviance residuals corresponding to best survival, intermediate as the two 
middle quartiles and poor survival as the quartile corresponding to the worst survival.  
 
In the next step, the relative risk of death among the index cases given the survival of their 
first-degree relative was estimated using the same Cox regression model as in the first step, 
additionally adjusting for potential family cluster effects. This analysis was performed 
among all index cases (N=1701) as well as limited to index cases that had the same type of 
lymphoid malignancy as their first-degree relatives (N=491), and among all lymphoid 
malignancies as well as among the seven categories hereof.       
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6 RESULTS AND INTERPRETATION 
 
6.1 Study I: Possible interaction between cigarette smoking and human 
leukocyte antigen DRB1 in risk of follicular lymphoma 
6.1.1 Results 
We analyzed three amino-acid haplotypes and the shared epitope (SE) in HLA-DRB1 for 
interaction with smoking status in risk of follicular lymphoma. Relative to never smoking in 
combination with no SE alleles, current smoking in combination with 2 SE alleles was 
associated with an increased risk of follicular lymphoma among all subjects (ORformer=2.20, 
95%CI 1.10, 4.41, ORcurrent=3.56, 95%CI 1.60, 7.92) and among women (ORformer=2.95, 95%CI 
1.18, 7.37, ORcurrent=5.63, 95%CI 2.07, 15.3; Table 7). However, there was no such increase 
associated with smoking status among all subjects or women carrying no or one SE allele. 
This was also the case among men irrespective of number of SE alleles carried (Table 7). The 
attributable proportion (AP) of follicular lymphoma risk due to interaction was 60% among 
all subjects (AP=0.6, 95%CI 0.15, 1.0) and 50% among women (AP=0.5, 95%CI 0.005, 1.0) 
who were current smokers and carried 2 SE alleles (Table 7). 
 
Table 7. Number of cases and controls and relative riska of follicular lymphoma by smoking 
status and number of shared epitope alleles in all study subjects and stratified by sex.  
 
NA= not appropriate. a Relative risk was estimated as odds ratios, OR, with 95% confidence intervals, CI. 
Regression models were adjusted for country, age and sex (the latter only when men and women were 
analyzed together). b Shared epitope (SE) alleles were defined as HLA-DRB1*04 or HLA-DRB1*10, excluding 
DRB1*0103, HLA-DRB1*0402 and HLA-DRB1*0403 when four-digit data was available. c Attributable 
proportion (AP) of interaction is presented for individuals exposed to both current smoking and two SE alleles.  
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6.1.2 Interpretation 
There is no other study exploring this or similar interactions in lymphoma risk to relate our 
results to. Accordingly, it is not possible to draw firm conclusions on the observed 
associations. If our results can be validated, it means that individuals carrying SE (or some 
other tightly linked amino-acid haplotype) are especially susceptible to follicular lymphoma 
upon smoking. From a public health perspective, this would mean that follicular lymphoma 
could be added to the list of diseases preventable by anti-smoking campaigns. The 
association could also teach us about mechanisms in lymphomagenesis. The differences in 
results observed for men and women could be due to considerably less men to analyze, 
resulting in less power than for the analysis of women. An interaction among men can thus 
not be excluded. Also, it is hard to imagine a biological explanation to the different results 
by sex observed in the study. Nevertheless, differences by sex has also been observed in 
studies of smoking in follicular lymphoma risk, as outlined above (see 2.2.1.1). Hopefully, we 
will see validation studies exploring this potential interaction in the near future.            
 
6.2 Study II: Life style factors, autoimmune disease and family history in 
prognosis of non-Hodgkin lymphoma overall and by subtype 
6.2.1 Results 
6.2.1.1 All-cause death 
Current compared to never smoking was associated with a worse survival among all NHL 
(HR= 1.5, 95% CI 1.2-1.8) and diffuse large B cell lymphoma (HR= 1.8, 95% CI 1.2-2.7) but not 
among other subtypes (Table 8). Former smoking was not associated with survival among 
patients with NHL overall or subtypes. Education (proxy for socioeconomic status) ≤9 years 
compared to >12 years was associated with a worse survival among NHL overall (HR= 1.3, 
95% CI 1.1-1.7). Summer sunbathing one or more times per week compared to zero times 
per week 5-10 years before lymphoma diagnosis was inversely associated with all-cause 
death among follicular lymphoma patients (linear trend test P= 0.03). In mantle cell 
lymphoma, this association went in the opposite direction (P= 0.03). There was no 
association with sunbathing among all NHL combined or other subtype. BMI was not 
associated with survival among all NHL or subtypes. Autoimmune disease was positively 
associated with risk of death among all NHL patients (HR= 1.4, 95% CI 1.0-1.8, P< 0.05). 
Having a family history of hematopoietic malignancy compared to not having such a history 
was borderline statistically significantly associated with worse survival among all NHL 
patients (HR= 1.5, 95% CI 1.0-2.0, P> 0.05) and there were no statistically significant 
associations by subtype.  
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6.2.1.2 Lymphoma-related death 
When exploring lymphoma-related death as the outcome, associations were generally 
weaker and statistically non-significant (data shown in supplement of published paper).159 
However, low versus high educational attainment was statistically significantly associated 
with lymphoma-related death among all NHL (HR= 1.3, 95% CI 1.0-1.6, P< 0.05) but not 
among subtypes. For smoking and autoimmune disease, the point estimates were similar for 
lymphoma-related death as those observed for all-cause death but did not reach statistical 
significance.   
 
Table 8. Multivariable-adjusted hazard ratios with 95% confidence intervals for all-cause 
death among patients with all NHL or subtypes.  
1 Adjusted for sex and age. 2 Stratified by age and spread/stage (primary extranodal; nodal stages 1 and 2; 
nodal stages 3 and 4; missing), and adjusted for sex, smoking, education and BMI. 3 Self-reported RA, SLE, 
Sjögrens syndrome or celiac disease.  
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6.2.2 Interpretation 
6.2.2.1 Smoking 
Smoking at diagnosis was consistently associated with an increased risk of death among NHL 
patients in our study as well as in three previous studies, although somewhat different 
smoking exposure measures were used.85,86,88 In addition, two more recent studies provide 
further evidence of this association.87,89 In a meta-analysis of four of previously published 
studies, smoking duration, intensity and pack-years but not smoking status were all 
associated with all-cause death among NHL patients.87 No study has reported a protective 
effect of smoking. Based on these six studies, it is reasonable to conclude that there is a link 
between smoking and survival among NHL patients.  
Regarding subtypes, there is less data published and there are inconsistencies between 
studies. Diffuse large B cell lymphoma survival was associated with smoking in our study and 
one previous study,88 while no association was observed in three studies including the meta-
analysis.85-87 Follicular lymphoma survival was associated with smoking in two out of five 
studies, including the meta-analysis.85-89 Chronic lymphocytic leukemia survival was also 
associated with smoking in two out of three studies, although not all exposure measures 
were significant.85,88,89 Less power when splitting up NHL into subtypes may be an 
explanation for the inconsistencies. More data is needed to draw conclusions on the effect 
of smoking by specific NHL subtypes. This is also the case for lymphoma-related/specific 
death.   
It is well-established that smoking causes life-threatening conditions, such as cancer and 
lung and cardiovascular diseases, in the general population.92 Comorbidities like these may 
cause a poorer performance status, which could make the caring physician to reduce 
treatment intensity with possible implications for prognosis.94 Chemotherapy could also 
aggravate comorbid conditions, also increasing the risk of death.94,95 Whether smoking 
directly interacts with cancer treatment is not known but could be a hypothesis.  
 
6.2.2.2 Education – socioeconomic status 
Low versus high socioeconomic status was consistently associated with increased risk of 
death among NHL patients in our study and two previous studies conducted in Denmark97,98 
and Scotland,96 respectively. The Danish study also used attained education as measure of 
socioeconomic status (along with some other measures, as described in 2.4.6.2), while the 
Scottish study used residential area. We also explored and demonstrated the same 
association with lymphoma-related death. The other two studies did not explore this 
outcome, nor survival by subtypes. There is no study showing a null or conflicting result. 
Together, available data suggest that socioeconomic status influences survival after NHL, 
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possibly through differences in disease stage at diagnosis96,98 and/or comorbidity (in parallel 
to the discussion for smoking above).160 However, no conclusions can be drawn regarding 
the potential variation of effect of socioeconomic status on lymphoma-specific death, nor 
the effect on survival among specific subtypes. 
 
6.2.2.3  Summer sunbathing habits 5-10 years before NHL diagnosis – UV radiation 
A potential effect of UV radiation might go through vitamin D production, as UV radiation is 
the most important source of active vitamin D. In our study, we did not observe any clear or 
consistent associations between sunbathing habits or other UV radiation exposures and 
outcome of NHL. Vitamin D insufficiency was associated with increased risk of death among 
patients with diffuse large B cell lymphoma or T cell lymphoma but not among patients with 
follicular lymphoma or mantle cell lymphoma in one study.104 Diffuse large B cell lymphoma 
was also associated with lymphoma-specific death in this study.104 Among two cohorts of 
follicular lymphoma patients, vitamin D insufficiency was associated with lymphoma 
progression, while an association with survival was observed in just one of the two 
cohorts.105 Although not conclusive, available data motivates further investigation of the 
effect of UV radiation and/or vitamin D status on survival of NHL and subtypes, since vitamin 
D supplementation would be an easy and readily available way to improve prognosis, should 
the findings be confirmed.  
 
6.2.2.4 Body mass index – obesity  
Our results do not support a link between obesity and survival in NHL patients overall or by 
subtype. Another three studies on the subjects have been published.86,89,100 Two of these 
three studies showed that obesity versus normal-weight was associated with increased risk 
of all-cause and lymphoma-specific death among NHL patients.86,89 The point estimates of 
the third study were in agreement with those of the two other studies but were not 
statistically significant.100 Regarding subtypes, obesity was associated with increased risk of 
death among patients with chronic lymphocytic leukemia in one89 of two studies.100 Survival 
of diffuse large B cell lymphoma and follicular lymphoma patients has not been associated 
with obesity in the three studies, in line with our findings.86,89,100 Hence, available data is not 
conclusive still. The prevalence of obesity was considerably lower among our study subjects 
compared to the three other studies (11% versus 18%89 20%100 and 26%86). Possibly, there 
were also more individuals with extreme obesity in these other studies. The resulting higher 
power in these three studies could possibly explain differences in results. Further studies are 
needed to draw conclusions about the impact of obesity on outcome in NHL and subtypes.   
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As discussed in 2.4.6.3, a possible link between obesity and NHL survival is hypothetical. One 
proposed hypothesis is that insulin resistance due to obesity increases the level of insulin-
like growth factor-1, leptin and cytokines, which all could stimulates cell growth and 
proliferation.101-103    
 
6.2.2.5 Autoimmune disease 
In our study, autoimmune disease was a composite variable of four diseases: RA, SLE, 
primary Sjögren’s syndrome and celiac disease. Although different diseases, it seems 
reasonable to assume that they all might confer worse or unchanged but not improved 
survival among NHL patients, perhaps through the associated long-standing inflammatory 
state. Our and other studies provide conflicting results in this area. Mikuls et al compared 
NHL patients with and without RA and found no association with all-cause death but 
observed a decreased risk of lymphoma-specific death and an increased risk of deaths due 
to other causes among NHL patients with concomitant RA.108 This latter finding could 
possibly be due to competing risks, since RA patients have an increased risk of death 
compared with the general population.161 Ji et al on the other hand found an increased risk 
of both all-cause and lymphoma-specific death among NHL patients with RA compared to 
NHL patients without RA.107 One study has assessed the impact of celiac disease on NHL 
survival and found no association.139  
 
Taken together, there is no clear answer to the hypothesis that having an autoimmune 
disease confers a worse prognosis when diagnosed with a NHL. The conflicting results could 
possibly be due to excess risk of death for some NHL subtypes but not others, and the 
proportion of these could vary between studies. Rituximab has improved the outcome of 
both B cell NHL and RA since it became available in the beginning of the millennium. Existing 
studies were conducted during somewhat different time periods (our study 1999-2010, 
Mikuls et al 1984-2002, Ji et al 1961-2006). Consequently, the proportion of patients that 
received rituximab as part of their NHL and/or RA treatment is probably different in the 
three studies, which possibly could influence the association between RA and NHL survival. 
A few studies have shown that autoimmune diseases such as RA may be linked specifically 
with the development of diffuse large B-cell lymphoma of the non-germinal center or 
activated B-cell type, which could have implications for survival.110  
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6.2.2.6 Family history of a hematopoietic malignancy 
There are no data that support an association between family history of a hematopoietic 
malignancy (our study), any lymphoma,112 or NHL113 and survival of NHL patients overall, 
although the association was borderline statistically significant in our study. There is one 
study of morbus Waldenström patients, which found an increased risk of death among 
those with a first-degree relative with any lymphoproliferative disorder compared to 
sporadic cases.162 One study on survival among patients with familial versus sporadic 
chronic lymphocytic leukemia found no difference.163  
 
One explanation for the general lack of association could of course be that no link exists 
between family history of a hematopoietic malignancy and NHL survival. Another 
explanation could be that some familial NHL cases may inherit protective traits while others 
inherit deleterious traits. Lumping together all familial cases may thus hide potential 
differences in survival. In line with this reasoning, one of the studies mentioned above 
demonstrated a non-significant concordance in survival among familiar cases.113 
Furthermore, several candidate gene studies have demonstrated both protective and 
deleterious single nucleotide polymorphisms in survival of all NHL and subtypes.114,115,118-
121,124 We further explored this further in Study III and IV.        
 
6.3 Study III: A comprehensive evaluation of the role of genetic variation in 
follicular lymphoma survival 
6.3.1 Results 
6.3.1.1 Genome-wide association studies and meta-analysis 
We found no SNP associated with lymphoma-specific death at the genome-wide significance 
level of P≤ 5.0 x10-8. We found four SNPs associated at a suggestive level (P≤ 10-6; Table 9). 
The smallest P value was borderline statistically significant (P= 5.24 x10-8) and was observed 
for a SNP on chromosome 17q in the ABCA10 gene. The other three were located on 
chromosome 1 in gene DAB1 (P= 2.22 x10-7), on chromosome 4 in-between genes (P= 2.24 
x10-6) and on chromosome 19 in the KLK11 gene (P= 9.38 x10-6). 
 
6.3.1.2 SNPs associated with follicular lymphoma outcome in previous studies 
Most SNPs reported to be associated with follicular lymphoma outcome in at least one 
previous study were not associated with lymphoma-specific survival or lymphoma 
progression in our study (Table 10). However, the SNP rs2466571 in CD46 (HR= 1.37, 95% CI  
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Table 9. The top single nucleotide polymorphisms (SNP) associated with lymphoma-specific 
deathA (Prandom≤ 10-6) in the meta-analysis of FL patients in SCALE and UCSF (N=586). SNPs in 
strong linkage disequilibrium (r2 ≥0.8) with the top SNPs but with larger P values are not 
included. 
 
A1= minor allele, A2= major allele, MAF= minor allele frequency, NA= not applicable;  
A Estimated with hazard ratios, HR, and 95% confidence intervals, CI, adjusting for sex, age at diagnosis and 
three principal components. The minor allele was investigated for association. B MAF was calculated in SCALE. 
 
Table 10. Relative riskA of lymphoma-specific death and lymphoma progression for selected 
SNPs previously associated with any follicular lymphoma outcome in at least one previous 
study.  
 
A Estimated with hazard ratios, HR, and 95% confidence intervals, CI. Adjusted for sex, age at diagnosis and 
three principal components. B Swedish cases only (N=231) for time to progression. C Imputed SNP. 
D rs6457327 has previously been associated with both FL risk and prognosis E Opposite direction of association 
to previous study.121 
The minor allele (A1) was investigated for association except for rs2466571 (CD46), where the major allele (A2) 
was used as reference for easier comparison with previous study results.  
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1.10-1.72, P=0.006), two tightly linked SNPs (r2=0.99) in IL8 (rs4073 HR= 0.78, 95% CI 0.62-
0.97, P= 0.02; rs2227307 HR= 0.75, 95% CI 0.60-0.94, P= 0.01) were associated with 
lymphoma progression. The smallest P value in our study (P= 0.0001) was observed for a 
SNP in MTHFR in association with lymphoma progression. One SNP in IL2 was significantly 
associated with lymphoma-specific death. After Bonferroni correction for multiple testing (2 
tests in 27 SNPs= 54 test) only the association with the SNP in MTHFR remained significant 
(corrected P= 0.01).       
 
6.3.2 Interpretation 
The new results we provide in the GWAS as well as the validation of previous findings are 
not enough to draw firm conclusions about whether these SNPs have true effects on 
follicular lymphoma outcome. None of our top findings (the top SNPs of the GWAS and the 
three SNPs of the validation study) were in fact statistically significant after taking multiple 
testing into account (either by setting a conservative significant level of P≤ 5.0 x10-8 or after 
Bonferroni correction). Nevertheless, the results are hypothesis generating. The top SNP of 
the GWAS was very close to being statistically significant and was located in ABCA10 and in a 
locus with other ABC transporter genes that theoretically could influence drug 
resistance.164,165 It would be interesting to see this finding (and also the other top hits) 
validated in other populations.  
 
The two SNPs in IL8 and the one in CD46 in the validation part of our study were at least 
nominally statistically significant (P< 0.05) in two or three cohorts, including our own. 
Hence, these results are the strongest in our investigation. IL8 is a major mediator of the 
inflammatory response and a potent angiogenic factor. CD46 is a cell membrane protein 
that inhibits complement components, protecting the cell from damage. Although any 
potential biological effect of the SNPs is unknown, their location in theoretically relevant 
genes along with the results from us and others motivate further studies to validate the 
results in other populations.  
 
Our results regarding the SNPs in MTHFR and IL2 are in conflict with previously reports, 
since the point estimate went in the opposite direction.121,166 
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6.4 Study IV: Concordance in survival of first-degree relatives diagnosed 
with a lymphoid malignancy 
 
6.4.1 Results 
We show evidence of a familial concordance in survival among first-degree relatives with a 
lymphoid malignancy (Table 11). A concordant survival was observed only among index 
cases with first-degree relatives that had the same type of lymphoid malignancy that were 
affected by any lymphoid malignancy (good vs poor: HR=1.86, 95% CI 1.31-2.63, P for trend= 
0.0004), a NHL (good vs poor: HR=1.86, 95% CI 1.21-2.86, P for trend= 0.006) or an indolent 
lymphoma including chronic lymphocytic leukemia (good vs poor: HR= 2.62, 95% CI 1.14-
6.03, P for trend= 0.03). Similar but non-significant trends were also observed for first-
degree relatives with chronic lymphocytic leukemia (P for trend= 0.08) or plasma cell 
malignancies (P for trend= 0.14). There was no association among patients with Hodgkin 
lymphoma, aggressive lymphoma or acute lymphocytic leukemia, although the number of 
observations here were small. When analyzing all index cases (both those with concordant 
and those with non-concordant subtypes as their first-degree relative), there was no 
statistically significant concordance in survival, although a borderline P value for trend was 
observed for all subtypes combined (P for trend= 0.06). Also of note, we did not see a 
familial concordance in survival among index cases with first-degree relatives with non-
concordant type of lymphoid malignancy (data not shown).  
 
6.4.2 Interpretation 
There is one related, small study that in complementary analyses investigated concordance 
in survival between 98 parents and 98 offspring with NHL and found a non-significant trend 
toward better survival in offspring that had parents that survived ≥24 months after NHL 
diagnosis as compared to offspring with parents that survived <24 months.113 Our study was 
much larger and accounted for what was good, expected and poor survival among patients 
diagnosed in different time periods, ages of diagnosis, sex, socioeconomic status and, 
importantly, with different types of lymphoid malignancies. The well-known higher 
heritability of indolent lymphoma risk, especially chronic lymphocytic leukemia, compared 
to aggressive lymphomas167,168 gave rise to much higher numbers of indolent lymphoma 
forms and thus also considerably higher power for analyses for these groups. Perhaps not 
surprisingly therefore, it was among indolent lymphomas that a statistically significant 
familial concordance in survival was observed. The vast majority of these were chronic 
lymphocytic leukemia patients and although the point estimates imply the same trend in 
this subtype alone it was not statistically significant. Taken together, our data clearly suggest   
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Table 11. Hazard ratio (HR) of death with 95% confidence intervals (CI) in index cases given 
the survival of their respective first-degree relative (good, expected or poor). Analyses were 
performed among all types of lymphoid malignancies together and separated by type 
among all index cases and limited to index cases with a first-degree relative with a 
concordant subtype.  
 
CLL= chronic lymphocytic leukemia, ALL= acute lymphoblastic leukemia 
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some heritability in survival among NHL patients, particularly among indolent lymphoma 
patients. The fact that first-degree relatives with different types of lymphoid malignancies 
did not demonstrate a similar familial concordance in survival makes variation in genetic 
factors related to lymphoma biology a more likely explanation than shared environmental 
factors or general genetic variation affecting for instance normal ageing. However, 
considerations regarding mechanisms remain speculative. 
 
 
 
6.5 CONSIDERATIONS OF BIAS 
 
6.5.1 Study I: Possible interaction between cigarette smoking and human 
leukocyte antigen DRB1 variation in risk of follicular lymphoma 
The study was of case-control design. It is thus important that the distributions of the risk 
factors among the control subjects are representative of the distributions in the population 
that gave rise to the follicular lymphoma cases. Unfortunately, material for DNA isolation 
was discarded among Swedish control subjects included in SCALE. Therefore, these subjects 
were not possible to use in this study. Instead, we borrowed Swedish control subjects from 
the EIRA study. These were randomly selected from the population that gave rise to the 
rheumatoid arthritis patients of the study, i.e. the population of Sweden (except the most 
Northern part). Thus far they should be representative also of the vast majority of the 
Swedish follicular lymphoma cases. The EIRA control subjects were matched against the 
rheumatoid arthritis patients on age, sex and regions of Sweden. Typical age at rheumatoid 
arthritis onset is 50-60 years and 70% are women, while these numbers in follicular 
lymphoma are 65 years and 50%.169,170 This was reflected in our study in that the EIRA 
control subjects consisted of more women than the Swedish SCALE control subjects (72% 
versus 56%), but the age distribution was very similar (interquartile range 48-62 versus 50-
62 years). The EIRA study also spanned over a longer time period. These circumstances 
could raise concern for the EIRA control subjects not being representative of the source 
population and thus cause biased estimates. HLA-DRB1 variation ought to be fairly constant 
over the study time period and also by age and sex, however. Smoking habits could vary by 
these factors, though. To make EIRA control subjects as representative as possible, only 
those included 1999-2003 were used in the study. Among these, the proportion never, 
former and current smokers among EIRA and Swedish SCALE controls were very similar 
(49%, 31%, 20% versus 48%, 33%, 19%). After this exercise we felt reasonably safe that the 
EIRA control subjects would be valid as comparators in our study. 
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We used imputed amino-acid data. We started out with genotyped genome-wide SNP data 
to densely impute approximately 72 000 SNPs across the HLA region, followed by 
imputation of 372 amino-acid positions and 263 HLA alleles. The accuracy of the 
imputations was tested in a subset of the samples and was found to be very high (>98% 
concordance). Misclassifications should thus be very few and also likely be randomly 
distributed among case and control subjects.  
 
6.5.2 Study II: Life style factors, autoimmune disease and family history in 
prognosis of non-Hodgkin lymphoma overall and by subtype 
Study II was a population-based cohort study (based on a case-control study, SCALE), 
covering the whole of Sweden. The participation rate was high: 84% for NHL overall, 84% for 
diffuse large B cell lymphoma and 94% for follicular lymphoma. The most common reason 
for non-participation among patients with diffuse large B cell lymphoma was early death 
(6%). This number among follicular lymphoma patients was 1%. Hence, there may have 
been a non-random selection process among patients with diffuse large B cell lymphoma 
(and possibly other aggressive NHL) in that the most aggressive cases in particular may have 
been missed. We can therefore not be sure that our results would be applicable to the most 
aggressive variants of diffuse large B cell lymphoma. The possible small selection among 
cases with follicular lymphoma (and perhaps other indolent lymphomas) should likely not 
have any practical consequence.  
 
Data on autoimmune disease, BMI, smoking, sun exposure and education attained were 
collected shortly after lymphoma diagnosis through a telephone interview. Retrospective 
collection of data may always be influenced by the study subjects’ ability to remember or 
willingness to report the actual value of a variable. This may not be a random process with 
regard to the outcome measure, especially in a case-control study, leading to 
misclassification that could give biased estimates. In this cohort investigation, however, all 
study subjects were lymphoma patients and they were unaware of the outcome when data 
was collected. Any misclassification would thus be randomly distributed among all study 
subjects, most often leading to a bias toward the null.  
 
To explore UV radiation and socioeconomic status we used proxy variables (summer 
sunbathing frequency the past 5-10 years and educational level attained). It can always be 
debated how well these proxies capture the exposure of interest, perhaps in particular our 
proxy for UV radiation exposure.  
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Our primary endpoint was all-cause death, which is not easily misclassified. For aggressive 
lymphomas, it is a fair measure of outcome, since these diseases progress fast and survival is 
short unless the patient is cured. Indolent lymphomas, however, are more like chronic 
diseases with a median survival of at least ten years. Since median age at diagnosis is high, 
many of the patients die from other causes than lymphoma. All-cause death may not be a 
good measure of prognosis in this group. Instead, lymphoma-related or lymphoma-specific 
death may better capture lymphoma progression.  
 
We did not have data on level of hemoglobin, lactate dehydrogenase, performance status, 
molecular prognostic markers or treatment. With the exception of performance status, it is 
hard to imagine how these established prognostic factors would be associated with the 
factors we investigated, however. Thus, it is uncertain to what extent not adjusting for them 
resulted in biased estimates. However, smoking, socioeconomic status, BMI and 
autoimmune disease are most likely associated with performance status through 
comorbidity (Figure 18). Comorbidity may in turn influence treatment intensity with possible 
implications for outcome, in particular among aggressive lymphomas that need intensive 
treatment to achieve cure. In this way of reasoning, performance status is on the causative 
path from exposures to outcome. Hence, we would possibly take away the association we 
were actually interested in measuring by adjusting for performance status. Autoimmune 
disease and family history of a hematopoietic malignancy may be associated with disease 
aggressiveness with implications for outcome. Disease aggressiveness may be reflected in 
level of hemoglobin and lactate dehydrogenase, as well as in disease stage at diagnosis. It 
could thus be argued that these factors should perhaps not be adjusted for either. Naturally, 
we were not able to account for unknown confounders.  
 
Nowadays, B cell lymphomas are treated with rituximab in addition to chemotherapy, which 
has improved survival for this group of patients. Whether the statistically significant results 
observed in our study would remain in the rituximab era is uncertain.  
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Figure 18. Directed acyclic graph for the associations investigated in Study I. The solid 
orange lines represent possible paths between investigated prognostic factors and one 
outcome. The dashed orange lines illustrates another possible path of association. The solid 
blue lines illustrates confounding associations. 
 
 
6.5.3 Study III: A comprehensive evaluation of the role of genetic variation in 
follicular lymphoma survival 
Study III was based on two cohorts: 1) SCALE, covering the whole of Sweden and Denmark 
(see 4.1), and 2) UCSF, covering the San Francisco Bay area (see 4.3). The participation rate 
was 94% for follicular lymphoma in SCALE and 69% overall in UCSF. Of those included in 
each study, blood samples were collected from 84% of follicular lymphoma cases in SCALE 
and 87% of all NHL cases in UCSF. Even though the UCSF cohort was of European ancestry it 
may be genetically somewhat different from the SCALE cohort. To account for variation in 
population makeup, both SCALE and UCSF cohorts were adjusted for population 
stratification and we used a random effects model when pooling the results. Furthermore, 
we do not know the reasons for nonparticipation in UCSF or not giving blood in SCALE and 
UCSF. Hence, we cannot excluded a non-random selection process here that could give rise 
to biased estimates.  
 
We imputed the values for six SNPs in the GWAS and 13 SNPs in the validation part of our 
study. Even though we used a well-established reference population (1000 Genomes) and 
only used imputed SNPs with high information score (>0.8), call rate (>0.9) and high 
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probability of being correct (>0.9) there may be some small misclassification. The 
misclassification should be random with regard to the outcome, however.  
  
We used lymphoma-specific death and lymphoma-progression as outcome measures in the 
study, both of which have the potential for misclassification. Any misclassification ought to 
be random, possibly reducing power. With regard to lymphoma progression, we used time 
till start of first line or second line treatment or lymphoma-specific death if no second line 
treatment was given as proxy. This definition may not be accurate. Because indication for 
treatment is symptoms due to follicular lymphoma, there is not much reason to look for 
tumor progression before the patient gets symptoms that could be related to that. The time 
elapsing from establishing tumor progression until start of treatment could also vary 
depending how fast the tumor grows. Although it may not be an accurate definition it still 
provides a measure of how fast the tumor grows that should work for our purposes. 
 
We performed multiple testing, indeed. This increases the risk of chance findings. This is 
why by convention the significance level is set at P≤ 5.0 x10-8 in GWAS studies these days. 
This P value corresponds to a significance level of 0.05 corrected for 1 000 000 tests using 
the Bonferroni method (0.05/1 000 000= 5.0 x10-8). This significance level is adopted to the 
number of SNPs normally found on genotyping chips nowadays. Hence, one could argue 
that this level was a bit too conservative for our GWAS, in which we conducted about 
330 000 tests (0.05/330 000= 1.5 x10-7). In the validation part of our study, we used the 
Bonferroni method to account for multiple testing. We have thus accounted for multiple 
testing. Chance findings cannot be excluded nevertheless. 
 
It is hard to imagine how factors in the follicular lymphoma international prognostic index 
(see 2.4.2.1) would affect germline genetic polymorphism. If anything, they may be on the 
association path from genetic trait to outcome (Figure 19). It is thus not obvious that these 
should be accounted for in the analysis. We included age and sex in the Cox model although 
also these variables do not clearly stand to reason. It has been practice in previous studies, 
however, and to present comparable results, we also accounted for these features. This may 
have mitigated potential associations under study. Other genetic traits may possibly 
confound our estimates but we do not know anything about this. Also, at this point we were 
not primarily trying to estimate the effect of each SNP on the outcome as accurately as 
possible but rather to find these potential risk SNPs for further validation in other cohorts.     
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Figure 19. Directed acyclic graph of the associations under study in Study III (solid orange 
line). The solid blue lines illustrates possible confounding associations.  
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6.5.4 Study IV: Concordance in survival of first-degree relatives diagnosed 
with a lymphoid malignancy 
This study was a register based cohort study covering the whole of Sweden. Apart from 
administrative limitations (such as the Multi-generation register being incomplete with 
regard parents data for individuals diseased before 1 July 1991), the national registers aim 
to include all eligible residents of Sweden. The registers used and the years covered in Study 
IV should be close to complete with regard to collected data. The largest proportion of 
missing data was observed for socioeconomic status (6% overall), collected from the 
censuses. This did not seem to be a random process, because those with unknown 
socioeconomic status had significantly worse survival relative to those with high 
socioeconomic status. In the Cox model, we adjusted for high, intermediate, low as well as 
having an unknown socioeconomic status.    
 
The drawback with using the national registers is the lack of clinical data. We were unable to 
do analyses based on detailed information on for example lymphoma subtype and account 
for prognostic scores or treatments. However, we could often distinguish Hodgkin from non-
Hodgkin lymphoma and plasma cell malignancies; aggressive from indolent lymphoma; 
chronic lymphocytic leukemia from other indolent lymphomas. In a rough way, differences 
in treatments were accounted for by adjusting for year of diagnosis. Parallel to my reasoning 
in Study III (see 6.5.2), it is not obvious which prognostic factors, such as prognostic scores, 
that would bias our estimates and should be accounted for in the regression models (Figure 
20). Just like in Study III, these may be on the association path between germline genetic 
variation and survival.  
     
 
Figure 20. Directed acyclic graph illustrating the association under study in Study IV (solid 
orange line). The dashed orange line illustrates the hypothetical mechanism that we tried to 
capture with our study. The solid blue lines represents confounding associations.  
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7 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
7.1 Study I: Possible interaction between cigarette smoking and human 
leukocyte antigen DRB1 variation in risk of follicular lymphoma 
The result of Study I supports our hypothesis of an interaction between smoking and HLA-
DRB1 polymorphisms in risk of follicular lymphoma. The mechanisms behind the putative 
association is unclear. However, the amino-acid positions in question are located in the 
antigen-binding groove of the HLA-DRB1 molecule, suggesting a role for differential antigen 
binding and/or presentation properties. It motivate confirmatory studies in larger datasets. 
The idea has been introduced in the InterLymph consortium and hopefully we will be able to 
perform such a validation study soon. The result also inspire studies of interaction between 
other environmental and genetic factors in follicular lymphoma and other NHL subtypes to 
help unravel mechanisms of association.  
 
7.2 Study II: Lifestyle factors, autoimmune disease and family history in 
prognosis of non-Hodgkin lymphoma overall and subtypes 
Available data clearly suggests that lifestyle factors, such as smoking and socioeconomic 
status, have an impact on survival after NHL diagnosis. Both low socioeconomic status and 
smoking are associated with increased occurrence of poor health due to comorbidities, 
which may explain the observed associations. Further investigation of these factors in larger 
datasets to confirm the associations and figure out the mechanisms behind would be 
interesting and could have clinical implications, e.g. to understand if associations are 
mediated through comorbidities or if they could be explained by differences in disease 
characteristics or treatment. Current prognostic scores used in clinical settings do not 
include host factors other than age and performance status, which is likely to provide only a 
very crude measurement of the host influence of survival. 
 
Regarding the impact of autoimmune disease on survival of NHL patients, available data 
motivates further studies, preferably both by specific autoimmune disease and by NHL 
subtype. To identify a sufficient number of these relatively rare patients, international 
collaboration will be necessary. InterLymph could be a good forum for this, or other settings 
such as the Nordic Lymphoma group.  
 
The mere fact that a patient with a lymphoid malignancy has a first-degree relative with a 
lymphoid malignancy does not seem to help to predict outcome. Risk factors for survival 
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may be subtype specific. Also, some inherited traits could be protective while others could 
be deleterious. As a suggestion, future studies are preferably conducted by subtype of 
lymphoid malignancy and take into consideration the fact that inherited traits could be both 
protective and deleterious (perhaps by defining survival using deviance residuals or the like, 
as in Study IV).     
 
7.3 Study III: A comprehensive evaluation of the role of genetic variation in 
follicular lymphoma survival 
Our study and others suggest a link between germline genetic variation and survival of NHL 
patients. Gene-expression profile studies and studies of the impact of the tumor 
microenvironment provide a (for the time being) hypothetical link. Although several 
candidates have been suggested, no specific single nucleotide or other polymorphism has 
yet been confidently identified. Based on Study III and previous studies, genetic variation in 
IL8 and CD46 are so far the strongest candidates to have prognostic impact in follicular 
lymphoma, suggesting importance of variation in immune function genes. Much is left to be 
done to confirm a link between germline genetic polymorphism and survival in NHL and to 
figure out the biological mechanisms behind.  
 
7.4 Study IV: Concordance in survival of first-degree relatives diagnosed 
with a lymphoid malignancy 
The results of Study IV provide further evidence of the hypothesis that common variants in 
the constitutional DNA may influence survival of patients with a lymphoid malignancy, 
although survival concordance in families may also be mediated through other mechanisms. 
The study supports such a link primarily among indolent lymphomas. Although no significant 
association was observed among patients with Hodgkin lymphoma, aggressive lymphoma or 
acute lymphoblastic leukemia, the few patients available for analyses within these groups 
preclude definitive conclusions. Given high quality register in the Nordic countries, 
collaboration within the Nordic Lymphoma group might provide a larger dataset that could 
validate the results of the present study and possibly allow analyses by subtypes.     
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7.5 FUTURE PERSPECTIVES  
 
 A validation study of the interaction between smoking and HLA-DRB1 variation in 
the risk of follicular lymphoma has been proposed to InterLymph. We will most likely 
see such a study in a near future.  
 
 We can expect to see studies of interaction between other environmental and 
genetic factors in the risk of follicular lymphoma as well as in other NHL subtypes. 
Although interaction studies are challenging to conduct, it is plausible that genes and 
environment interact in disease development. 
 
 The role of host factors in the prognosis of NHL subtypes should be further explored 
within large international collaborations with information about established 
prognostic factors and ideally among patients following similar treatment schemes. 
Other host factors than age, sex and performance status may prove valuable when 
predicting the prognosis of NHL patients in the future. With the introduction of new 
targeted treatments in NHL, associations between host factors and outcome may 
also be subject to change. 
 
 We will likely see more comprehensive studies of the prognostic impact of host 
genetic variation. This area may provide some answers to the variation in clinical 
trajectories between seemingly identical NHL that we cannot explain today. 
Ultimately, increased knowledge of this field will hopefully lead to predictive 
markers of response to a certain treatments and/or new, effective treatment 
approaches.    
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
Denna avhandling handlar om en grupp elakartade sjukdomar som kan samlas under 
rubriken non-Hodgkin lymfom (NHL). Det är en något intetsägande rubrik – det enda den 
egentligen säger är att sjukdomen i fråga inte är ett Hodgkin lymfom. NHL begreppet lever 
ändå kvar och används även i denna avhandling. NHL består av ett 40-tal olika subtyper, 
som skiljer sig väsentligt åt i kliniskt förlopp och hur de svarar på våra behandlingar. De har 
gemensamt att de är elakartade sjukdomar utgångna från lymfocyter, dvs. en sorts vita 
blodkroppar. Oftast handlar det om B-celler (90%) men ibland T/NK-celler (10%).  
 
Även om NHL som grupp ligger på topp 10-listan över de vanligaste cancersjukdomarna i 
Sverige (och västvärlden för övrigt) är varje subtyp förhållandevis ovanlig. Pga. detta har 
många forskningsstudier gjorts på NHL som grupp. Ju mer kunskapen ökat har skillnaderna 
mellan subtyperna blivit tydligare. Det är nu uppenbart att vissa risk- och prognosfaktorer är 
gemensamma för NHL som grupp men att många är specifika för enskilda subtyper. I denna 
avhandling ingår studier både på NHL som grupp och enskilda subtyper. 
 
För de flesta av våra NHL-patienter vet vi inte orsaken till att sjukdomen uppstod. Det är 
välkänt att ett hämmat immunförsvar, t.ex. pga. HIV eller efter organtransplantation, klart 
ökar risken för NHL. Vissa infektioner är kopplade till NHL-utveckling, såsom Epstein-Barr 
virus och Helicobacter pylori. Huruvida livsstilsfaktorer spelar roll för risken att utveckla NHL 
är inte helt klart, även om flera studier pekar på det. Det är också mycket som talar för att 
normal variation i vårt DNA spelar roll för risken att insjukna i NHL. Vissa genetiska varianter 
minskar risken att insjukna medan andra ökar den. Den genetiska variation vi undersökte 
var av typen där ett baspar i DNA-strängen bytts ut mot ett annat (engelska: single 
nucleotide polymorphism, SNP). Ofta spelar detta byte ingen roll men i enstaka fall kan det 
till exempel leda till att en aminosyra i ett protein byts ut mot en annan, vilket skulle kunna 
påverka proteinets funktion. 
 
För en vanlig NHL-subtyp som heter follikulärt lymfom finns ett antal studier som talar för 
att rökning ökar risken att insjukna men alla studier är inte helt överens. Det finns också 
belägg för att SNP:ar i en gen som kodar för molekylen HLA-DRB1 påverkar 
aminosyrasekvensen i proteinet, vilket har kopplats till risken att insjukna i follikulärt 
lymfom. I Studie I i denna avhandling undersökte vi detta närmare. Vår hypotes var att 
rökning ökar risken för follikulärt lymfom särskilt hos personer som har vissa 
aminosyrakombinationer i HLA-DRB1- molekylen jämfört med personer utan dessa 
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varianter. I studien kunde vi påvisa ett sådant samband: jämfört med personer som aldrig 
rökt och inte bar på en variant av HLA-DRB1 kallad shared epitope ökade risken att insjukna 
gradvis så att personer som var före detta rökare och bar på shared epitope hade 2,2 gånger 
högre risk medan personer som var rökare och bar på shared epitope hade 3,5 gånger högre 
risk att insjukna. Detta var tidigare inte undersökt för NHL och behöver verifieras i andra och 
gärna större studier. Om fyndet står sig kan follikulärt lymfom läggas till listan över 
sjukdomar där risken ökar pga. rökning. Det kan också lära oss något nytt om mekanismerna 
som leder till att follikulärt lymfom uppstår.  
 
Vad gäller prognosen för NHL så är den helt beroende av vilken subtyp det handlar om. 
Högmaligna lymfom, såsom diffust storcelligt B-cellslymfom, leder till döden inom några 
månader utan behandling men är oftast botbara med medicinsk behandling. Lågmaligna 
lymfom, såsom follikulärt lymfom, är vanligen inte botbara men växer långsamt. De 
behandlas vid symtom och hälften av patienterna lever fortfarande 10 år efter diagnos. 
Prognosen varierar dock påtagligt även inom varje subtyp av NHL, vilket vi inte har kunskap 
att förstå ännu. För de vanligaste NHL-subtyperna finns prognostiska index, där summan av 
ett antal riskfaktorer placerar en patient i en prognosgrupp. Patientens ålder och 
prestationsförmåga (engelska: performance status) ingår nästan alltid. Prognosgrupperna 
som finns kan dock endast grovt förutsäga förloppet. Därför har studier gjorts av andra 
värdfaktorer sista åren med hopp om att hitta nya markörer med prognostiskt värde. I detta 
område ingår även studier om huruvida nedärvd genetisk variation i form av SNP:ar kan 
förklara skillnaden i överlevnad inom olika NHL subtyper. Betydelsen av värdfaktorer, 
inklusive nedärvd genetisk variation, för överlevnaden vid lymfom var fokus för Studie II-IV i 
denna avhandling.  
 
I Studie II undersökte vi om det fanns ett samband mellan överlevnad och rökning, 
socioekonomiskt status (i vårt fall utbildningsnivå), fetma, exponering för ultraviolett ljus, 
autoimmun sjukdom eller om man hade en familjemedlem som drabbats av en blodcancer 
(inklusive lymfom). Vi kunde visa att NHL patienter som rökte, hade låg utbildningsnivå eller 
var drabbad av en autoimmun sjukdom dog i större utsträckning än NHL patienter utan 
dessa faktorer. För rökning och lågt socioekonomisk status finns stöd för våra resultat i 
andra studier. Vi vet inte säkert varför det är såhär men en hypotes med visst stöd är att 
både rökning och lågt socioekonomisk status är förknippade med ökad sjuklighet (såsom 
hjärtkärlsjukdom) som kan påverka våra möjligheter att behandla lymfomsjukdomar.        
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I Studie III och IV undersökte vi om nedärvd genetisk variation påverkade överlevnaden för 
patienter med follikulärt lymfom (Studie III) eller en lymfoid malignitet (Studie IV). I Studie III 
undersökte vi dels om någon av cirka 300 000 SNP:ar spridda över DNA-strängarna 
påverkade risken att dö av lymfomrelaterade orsaker (del 1), dels om 22 SNP:ar som 
rapporterats påverka prognosen för patienter med follikulärt lymfom i tidigare studier också 
gjorde det i vårt patientmaterial (del 2). I del 1 kunde vi inte med säkerhet påvisa någon SNP 
som påverkade överlevnaden, även om effekten av en SNP i en gen med eventuell koppling 
till läkemedelsresistens stod ut och vara nära att vara statistiskt säkerställd. I del 2 fann vi i 
likhet med tidigare studier att två SNP:ar i genen för interleukin 8 (som påverkar funktioner i 
vårt immunförsvar) och en SNP i genen CD46 (som påverkar komplementsystemet i vårt 
immunförsvar) påverkade prognosen för patienter med follikulärt lymfom. Dessa fynd 
behöver stöd i ytterligare studier innan man kan dra säkra slutsatser. Om fyndet kan 
bekräftas innebär det dels en ökad förståelse för de mekanismer som påverkar 
sjukdomsförloppet och möjligen även nya mål att rikta behandling mot.        
 
I Studie IV sökte vi stöd för att nedärvd genetisk variation påverkar överlevnaden vid 
lymfoida maligniteter (= Hodgkinlymfom och non-Hodgkinlymfom, inklusive sjukdomar som 
myelom och akut lymfatisk leukemi). Vår hypotes var att om det finns en nedärvd 
komponent som påverkar överlevnaden vid lymfoida maligniteter så borde två 
familjemedlemmar med en lymfoid malignitet ha liknande överlevnadstid. För studien 
använde vi information från svenska register, som gjorde det möjligt för oss att koppla ihop 
individer inom en familj (två eller fler) som drabbats av en lymfoid malignitet. I studien 
kunde vi visa att inom familjer där två eller fler medlemmar hade samma typ av lymfoid 
malignitet fanns en samstämmighet i överlevnadstid. Med andra ord, personer vars 
familjemedlem hade en god prognos hade själva en god prognos, medan personer vars 
familjemedlem hade en dålig prognos själva hade en dålig prognos. Sambandet kunde också 
påvisas mer specifikt hos personer med lågmalignt NHL. Denna studie motiverar att vi 
fortsätter studera betydelsen av nedärvd genetisk variation för överlevnaden vid lymfoida 
maligniteter.     
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